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Abstract 
 
The goal of this research is to understand how three different parameters affect single 
chain variable fragment (scFv) binding capacity. The parameters that were varied include the 
number of variable complementarity determining regions (CDRs), the number amino acids used 
to diversify CDRs, and configuration of the structure. How the parameters affect the binding 
capacity will be tested using the yeast two hybrid assay against five different protein domains. 
Eight scFv libraries were generated; the genes expressing the scFvs were constructed and the 
CDRs were randomized using PCR amplification. Genes expressing scFvs were cloned, using 
the homologous gap repair mechanism in Saccharomyces cerevisiae. Representative members of 
scFv libraries were sequenced to confirm correct construction. 
Library diversity was calculated from the library transformation efficiency. 
Transformation efficiency refers to the number of cells that grew at the time of transformation of 
the scFv gene into yeast cells. There were significant differences in the diversity of the scFv 
libraries, which created difficulty in comparing the library binding capacities. Sequencing the 
scFv libraries revealed that on average 50% of each library contained correct scFv sequences. 
The percent of correct sequences within each library was then used to calculate the functional 
diversity. 
The yeast two-hybrid assay was used to screen the scFv libraries for interactions and to 
test binding capacity. The binding capacity of the scFv libraries was tested and compared in five 
different yeast two-hybrid assays using five protein domains as the targets for each screen.  
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The screening results showed that in all cases cyclic scFv libraries had a statistically 
significant higher binding capacity than linear scFv libraries despite a diversity bias against the 
cyclic libraries. There was no clear trend in binding capacity with the other two parameters; 
however, the four amino acid three CDR libraries dominated over the other libraries in almost 
every screen. 
Some of the scFvs isolated from the screens were expressed in E. coli and S. cerevisiae to 
analyze for proper expression and correct size. All the scFvs that were isolated and analyzed 
were the correct size and could be purified using a poly histidine tag. 
Due to its bioaffinity and specificity, scFvs were constructed to profile disease patterns, 
and to identify potential drug targets. In addition to its original application to health-related 
studies, scFvs could also be extended to locate potential metabolic bottlenecks, to alter metabolic 
flux to enhance productivity, and regulate metabolic bionetworks. Industrial microorganisms are 
generally carrying more than two sets of chromosomes, making it difficult to be genetically 
engineered when conventional approaches are employed. With the availability of scFvs as 
reported in this thesis, we are able to design specific scFvs that selectively bind to target proteins, 
resulting in re-routing of metabolic flux within the microorganism, toward a high productivity of 
desired product. ScFvs can be applied to industrial microorganisms directly, leading to the 
development of new fermentation processes. 
 iv 
 
Acknowledgements 
I would like to sincerely thank my supervisor Dr. Yen-Han Lin for all his support and 
guidance through my studies and for supporting this collaboration. I am very grateful and 
fortunate to have received his continuous encouragement and feedback.  
I would like to thank my co-supervisors Drs. C. Ron Geyer and Steve Sanche for their 
continuous support. Dr. Geyer initially hired me as a summer student; his novel ideas and 
enthusiasm encouraged me to pursue my Masters degree. His mentorship and direction has 
played a major role in my training and success through my graduate program. 
My graduate committee including Drs Catherine Niu and Mehdi Nemati for their 
continuous support and feedback on my research project and reports.  
I would also like to thank all the members of Dr. Geyer and Dr. DeCoteau’s lab, 
especially Kris Barreto who helped with numerous aspects of my project; Dr. John DeCoteau for 
allowing me to use equipment and reagents from his lab and for his insightful comments during 
lab meetings. Karen Mochoruk for assistance with the mass spectrometer and making sure I 
always had reagents to do my experiments. 
Lastly, I would like to send a special thanks to my family who have always supported and 
encouraged me along the way. 
 
  v 
 
Table of Contents 
page 
 
Permission to Use .......................................................................................................................... i 
Abstract .........................................................................................................................................ii 
Acknowledgements...................................................................................................................... iv 
Table of Contents.......................................................................................................................... v 
List of Tables .............................................................................................................................viii 
List of Figures .............................................................................................................................. ix 
List of Abbreviations ...................................................................................................................xi 
Glossary .....................................................................................................................................xiii 
Chapter 1 Introduction .................................................................................................................. 1 
1.1 Background ......................................................................................................................... 1 
1.2 Objectives ........................................................................................................................... 4 
1.3 Approach............................................................................................................................. 4 
1.4 Thesis Organization ............................................................................................................ 5 
Chapter 2 Literature Review......................................................................................................... 6 
2.1 Natural antibodies and scFvs .............................................................................................. 6 
2.2 Applications of scFvs.......................................................................................................... 9 
2.3 Considerations in scFv library design............................................................................... 12 
2.3.1 Number of variable CDRs....................................................................................... 12 
2.3.2 Varied amino acids within the CDRs...................................................................... 13 
2.4 Stability Limitations in ScFv Expression ......................................................................... 15 
2.5 Inteins and protein cyclization .......................................................................................... 17 
2.6 Screening combinatorial scFv libraries............................................................................. 20 
Chapter 3 Materials and Methods ............................................................................................... 24 
3.1 Microorganisms and Media ....................................................................................... 24 
3.1.1 S. cerevisiae Strains ................................................................................................ 24 
3.1.2 E. coli ...................................................................................................................... 27 
3.1.3 Vectors .................................................................................................................... 27 
  vi 
3.2 Primer design for yeast amplification and CDR construction .......................................... 27 
3.3 Construction of ScFv and ScFv Library Design ............................................................... 28 
3.3.1 ScFv Framework Gene Construction ...................................................................... 28 
3.3.2 Cloning the ScFv Framework into Yeast Expression Vector ................................. 31 
3.3.3 CDR Library Oligonucleotides ............................................................................... 32 
3.3.4 Cloning Degenerate Heavy Chain CDR H3 into ScFv Framework........................ 35 
3.3.5 Cloning Degenerate Heavy chain CDR H1 and CDR H2 ...................................... 37 
3.3.5 Mutating Light chain CDR L3 in ScFv................................................................... 38 
3.3.6 Cyclization of the ScFv Library.............................................................................. 39 
3.4 ScFv Yeast Two-Hybrid Interaction Mating Assay.......................................................... 42 
3.4.1 Protein Domains used in Diploid Construction ...................................................... 42 
3.4.2 Diploid construction................................................................................................ 43 
3.4.3 Yeast Two-Hybrid Interaction Assay ..................................................................... 45 
3.4.4 Quantitative Analysis for the Screening Results..................................................... 45 
3.5 Protein Expression of ScFv Constructs............................................................................. 46 
3.5.1 Expression of ScFv Proteins in Yeast ..................................................................... 46 
3.5.1.1 Protein L purification of scFvs ..................................................................... 46 
3.5.1.2 Western blotting............................................................................................ 47 
3.5.2 Expression of ScFv Proteins in E. coli.................................................................... 47 
3.5.2.1 Cloning scFvs into an inducible E. coli expression vector ........................... 47 
3.5.2.2 Histidine tag-Ni column purification ............................................................ 50 
3.5.2.3 Renaturation of the scFv protein................................................................... 50 
3.5.2.4 Protein L purification of scFvs ..................................................................... 51 
3.5.2.5 SDS-PAGE ................................................................................................... 51 
Chapter 4 Results ........................................................................................................................ 52 
4.1 Construction of Libraries .................................................................................................. 52 
4.1.1 Diversity of libraries ............................................................................................... 56 
4.1.2 Cyclization of scFv libraries ................................................................................... 58 
4.2 Library Screening.............................................................................................................. 60 
4.2.1 Protein domains used in the interaction mating assay ............................................ 61 
4.2.2 Screen Results ......................................................................................................... 62 
4.2.3 Cyclic versus linear in binding capacity ................................................................. 63 
4.2.4 Binding capacity of three and four variable CDRs ................................................. 65 
4.2.5 Two variable amino acids versus four in CDR variability...................................... 68 
4.3 Expression of scFv constructs........................................................................................... 70 
4.3.1 ScFv expression in S. cerevisiae ............................................................................. 70 
4.3.1.1 ScFv expression time course in S. cerevisiae ............................................... 71 
4.3.1.2 ScFv protein L purification........................................................................... 73 
4.3.2 ScFv expression in E. coli................................................................................ 73 
4.3.2.1 ScFv expression time course in E. coli ......................................................... 73 
4.3.2.2 ScFv histidine tag-nickel column purification.............................................. 75 
4.3.2.3 Renaturation of scFv ..................................................................................... 77 
4.3.2.4 Protein L purification of scFv ....................................................................... 79 
Chapter 5 Discussion .................................................................................................................. 81 
  vii 
Chapter 6 Conclusion.................................................................................................................. 85 
Chapter 7 Recommendations ...................................................................................................... 86 
List of References ....................................................................................................................... 87 
Appendix..................................................................................................................................... 96 
  viii 
 
List of Tables 
 
Table               page 
Table 3-1: Oligonucleotides used in this study........................................................................... 25 
Table 3-2: Explanation of the library names............................................................................... 33 
Table 3-3: Primers used in the construction of the CDRs. ......................................................... 35 
Table 3-4: Baits Used in each Screen. ........................................................................................ 44 
Table 4-1: ScFv library diversities.............................................................................................. 57 
Table A-1 Raw Screen Data. ...................................................................................................... 96 
 
  ix  
 
List of Figures 
 
Figure               page 
Figure 2-1: Full length antibody, Fab fragment and Fv fragments............................................... 7 
Figure 2-2: ScFv structure and CDR folding and binding model................................................. 8 
Figure 2-3: ScFv structure and aggregation................................................................................ 16 
Figure 2-4: cis and trans splicing of inteins. .............................................................................. 18 
Figure 2-5: Intein mediated protein cyclization.......................................................................... 19 
Figure 2-6: ScFv yeast two-hybrid assay.................................................................................... 23 
Figure 3-1: ScFv Framework Gene Construction....................................................................... 30 
Figure 3-2: ScFv Framework. ..................................................................................................... 30 
Figure 3-3: Yeast Protein Expression Vector pIL500................................................................. 31 
Figure 3-4: Linear scFv (framework) cloned into pIL500.......................................................... 32 
Figure 3-5: Positions of diversified complementarity determining regions (CDRs).................. 33 
Figure 3-6: Cloning CDR H3 into the scFv framework. ............................................................ 36 
Figure 3-7: Location of ß-galactosidase scFv CDR H3.............................................................. 37 
Figure 3-8: Cloning in CDR H1, FR2, and CDR H2.................................................................. 38 
Figure 3-9: Mutational PCR of light chain CDR L3. ................................................................. 39 
Figure 3-10: PCR amplification to cyclize the scFv libraries..................................................... 40 
Figure 3-11: Cyclic scFv cloned into yeast expression vector. .................................................. 41 
Figure 3-12: pEG202 yeast expression vector. ........................................................................... 43 
Figure 3-13: pET28b E. coli expression vector. ......................................................................... 49 
  x  
Figure 4-1: ScFv libraries created............................................................................................... 54 
Figure 4-2: SDS-PAGE analysis of scFvs expressed in E. coli. ................................................. 59 
Figure 4-3: Ratios comparing cyclic configuration to linear. ..................................................... 64 
Figure 4-4: Ratios comparing three CDRs to four CDRs. .......................................................... 67 
Figure 4-5: Ratios comparing two amino acids to four amino acids. ......................................... 69 
Figure 4-6: Cyclic scFv expressed in S. cerevisiae..................................................................... 71 
Figure 4-7: ScFv constructs expressed in S. cerevisiae. ............................................................. 72 
Figure 4-8: ScFv expression in E. coli........................................................................................ 74 
Figure 4-9: ScFv constructs expressed in E. coli. ....................................................................... 75 
Figure 4-10: ScFv purification from E. coli................................................................................ 76 
Figure 4-11: ScFv expression and renaturation. ......................................................................... 78 
Figure 4-12: ScFv Protein L purification.................................................................................... 79 
 
  xi  
 
List of Abbreviations 
 
Ade2   Gene involved in adenine biosynthesis 
BCR-ABL  Breakpoint cluster region – ableson kinase 
CC1-72  Coiled–coil domain, amino acids 1-72 of BCR 
CDR   Complementarity determining region 
cK3   Cyclic, four amino acid three CDR scFv library 
cK4   Cyclic, four amino acid four CDR scFv library 
cT3   Cyclic, two amino acid three CDR scFv library 
cT4   Cyclic, two amino acid four CDR scFv library 
dNTPs   DeoxyNucleotide TriPhosphates 
Fab   Fragment antigen binding 
H1   Complementarity determining region one on the heavy chain 
H2   Complementarity determining region two on the heavy chain 
H3   Complementarity determining region three on the heavy chain 
His3   Gene involved in histidine biosynthesis 
IC   C-terminal domain of the intein 
IN   N-terminal domain of the intein 
L1   Complementarity determining region one on the light chain 
L2   Complementarity determining region two on the light chain 
L3   Complementarity determining region three on the light chain 
  xii  
lacZ   Reporter gene encoding ß-galactosidase 
Leu2   Gene involved in leucine biosynthesis 
LK3   Linear four amino acid three CDR scFv library 
LK4   Linear four amino acid four CDR scFv library 
LT3   Linear two amino acid three CDR scFv library 
LT4   Linear two amino acid four CDR scFv library 
MATa   S. cerevisiae mating type a 
MATα    S. cerevisiae mating type α  
Npu   Nostoc punctiforme 
Oligo   Oligonucleotide 
PCR   Polymerase chain reaction 
ScFv   Single chain variable fragment 
SD   Synthetic dropout 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SH2   Src homology 2 
SH3   Src homology 3 
Ssp   Synechocystic species 
Taq   Thermos aquaticus 
Trp1   Gene involved in tryptophan biosynthesis 
Ura2   Gene involved in uracil biosynthesis 
Ura3   Gene involved in uracil biosynthesis 
YPD(A+)  Yeast peptone dextrose (with adenine added) 
  xiii  
 
Glossary 
 
:: means “replaced by” in describing strains, where lowercase lettering 
indicates a gene that is knocked out, uppercase indicates a functional gene; 
For example: “leu2::LexA6op-LEU2” means leu2 was replaced by six 
LexA operons and the Leu2 gene 
 
Ade2 Gene encoding the enzyme phosphoribosylaminoimidazole carboxylase 
which catalyzes a step in the purine nucleotide biosynthetic pathway 
 
Ampicillin  Antibiotic used in plasmid selection in E. coli. 
 
Anti-β-galactosidase Refers to an antibody or scFv that is specific for β-galactosidase 
 
Antibody Protein produced by the immune system; removes foreign organisms and 
objects by binding them with high specificity and affinity. 
 
Antigen Antibody or antibody fragment target 
 
Bait In a yeast two-hybrid screen, the target protein or protein of interest 
screened against other proteins to find an interacting protein. 
 
BCR-ABL A tyrosine-kinase oncogene expressed in chronic myeloid leukaemia; 
created from the Philadelphia-chromosome translocation; the Abelson 
leukaemia-virus protein (ABL) is fused with the breakpoint-cluster region 
(BCR). 
 
CC1-72 Coiled coil domain, BCR-ABL protein domain that forms a bundle of two 
or three alpha helices and can be involved in protein interactions 
 
CDR Complementarity Determining Region, found on antibodies and scFvs, 
forms loops that have affinity and specificity for the target antigen 
 
cK3 Cyclic scFv library containing three variable heavy chain CDRs and one 
variable light chain CDR (L3) varied with two different amino acids, 
tyrosine, serine, aspartate and alanine. 
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cK4 Linear scFv library containing three variable heavy chain CDRs and one 
variable light chain CDR (L3) varied with four different amino acids, 
tyrosine, serine, aspartate and alanine. 
 
Clone   To insert a gene of interest into a vector for expression inside a cell. 
 
Codon Three letter code made from four different DNA bases which code for 
different amino acids. 
 
Co-transformation Introduction of more than one foreign DNA molecules into a cell. 
 
cT3 Cyclic scFv library containing three variable heavy chain CDRs varied 
with two different amino acids, tyrosine and serine. 
 
cT4 Cyclic scFv library containing three variable heavy chain CDRs and one 
variable light chain CDR (L3) varied with two different amino acids, 
tyrosine and serine. 
 
Degenerate In reference to codons, a codon that can code for more than one amino 
acid. 
 
Diploid A yeast cell consisting of both mating types a and α; will also express two 
different plasmids, that of an scFv and that of a target protein domain. 
 
dNTPs   DeoxyNucleotide TriPhosphates or DNA monomers. 
 
EcoRI Restriction enzyme that cuts the DNA sequence G|AATTC between the G 
and A, isolated from E. coli RY13. 
 
Electrocompetent A bacterial cell that can be transformed using electroporation. 
 
Electrophoresis Migration of a DNA sample through a medium under the influence of an 
electric field to separate the different DNA samples. 
 
Electroporation A way to transform bacterial cells using an electrical shock that induces t 
   transient pores in the cells through which DNA can enter. 
 
Endonulcease  Enzyme that specifically cleaves the phosphodiester bond in DNA.  
 
Fab Fragment antigen binding; an antibody fragment composed of the N-
terminal half of the heavy chain and its associated light chain. 
 
Functional scFv An scFv containing the proper sequences determined by sequencing. 
 
Gel purification To separate DNA through an agarose gel, cut the desired DNA out of the 
gel and clean it up to obtain pure DNA from other contaminating DNA. 
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H1/H2/H3 Refers to a specific CDR region within the heavy chain (ie H2 refers to 
CDR 2 on the heavy chain). 
 
Hck   Hemopoietic cell kinase, may be involved in chronic myeloid leukaemia. 
 
Heavy chain  The large polypeptide subunit of an antibody. 
 
His3 Gene encoding imidazole glycerol-phosphate dehydratase, which 
catalyzes the sixth step in histidine biosynthesis. 
 
Histidine  tag Five or six consecutive histidines attached to a protein; has high affinity to 
nickel which is used to purify the tagged protein. 
 
Homologous  A natural DNA gap repair system found in yeast; can be used to clone 
  Recombination 
 
IC Domain  The IC domain of the Ssp self splicing split intein. 
   
IN Domain  The IN domain of the Npu self splicing split intein. 
   
Intein In this study the Ssp IC domain and Npu IN domain were used to catalyze a 
cyclization reaction cyclizing the scFv. 
 
Kanamycin  Antibiotic used in plasmid selection in E. coli. 
   
L1/L2/L3 Refers to a specific CDR region within the light chain (ie H2 refers to 
CDR 2 on the light chain). 
   
lacZ   Reporter gene that encodes β-galactosidase. 
 
Leu2 LEU2 encodes the enzyme beta-isopropylmalate dehydrogenase, the en 
catalyzes the third step in leucine biosynthesis. 
   
LexA operator  DNA sequence that LexA binds to with high efficiency. 
  
LexA8op  Containing eight LexA operators. 
 
Library (in this study) A collection of yeast cells each expressing an scFv with a 
different CDR sequence 
  
Ligase   An enzyme that joins two DNA molecules together.  
  
Ligation  The joining of two DNA molecules using a ligase.   
 
Light chain  The small polypeptide subunit of an antibody. 
  xvi  
   
Linker Short peptide made up of a three [Ser(Gly4)]3 used to tether the heavy 
chain to the light chain and to aid in cyclization of scFv proteins by 
allowing scFv conformation to stay unchanged. 
   
LK3 Linear scFv library containing three variable heavy chain CDRs varied 
with four different amino acids, tyrosine, serine, aspartate and alanine.  
  
LK4 Linear scFv library containing three variable heavy chain CDRs and one 
variable light chain CDR (L3) varied with four different amino acids, 
tyrosine, serine, aspartate and alanine.  
  
LT3 Linear scFv library containing three variable heavy chain CDRs varied 
with two different amino acids, tyrosine and serine.  
  
LT4 Linear scFv library containing three variable heavy chain CDRs and one 
variable light chain CDR (L3) varied with two different amino acids, 
tyrosine and serine. 
   
Lysate   All material left from the lysis of a cell. 
   
MATa   S. cerevisiae mating type a. 
 
MATα    S. cerevisiae mating type α  
 
Npu IN domain from Npu DnaE (Nostoc punctiforme, strain PCC73102, DNA 
polymerase III alpha subunit). 
   
Oligonucleotide A short DNA sequence. 
 (oligo or primer)    
 
PCR   Polymerase Chain Reaction, the process of amplifying DNA   
 
pESC-Hck  A plasmid expressing Hck.  
 
Phage   A bacterial virus. 
 
Phage display A technique used to fuse and display a foreign peptide or protein on a 
phage cell surface. The phage are screened to see what targets bind to the 
expressed fusion protein displayed on the phage surface. 
  
pIL500  Vector used to express scFv library proteins; Contains kanamycin  
   resistance, and yeast two-hybrid machinery including reporter genes. 
   
Protein L A protein that binds to antibodies and scFvs through their light chain; 
isolated from the bacteria Peptostreptococcus magnus. 
  xvii  
   
Recombination  way to introduce foreign DNA into a vector where two linear strands of 
DNA containing complementary sequences will join together to create one 
DNA molecule. 
  
Reporter gene Expression determines if an scFv interacts with a protein domain in the 
yeast two-hybrid system. 
   
Restriction site Specific sequence of DNA that is recognized and cut by a restriction 
enzyme in a specific location. 
   
ScFv Single chain variable fragment, intrabody or intracellular antibody; an 
antibody fragment that is made from a light chain variable domain and a 
heavy chain variable domain from an antibody.  
 
ScFv library Collection of yeast cell expressing scFv proteins varied by their CDR 
composition. 
   
SD    Synthetic dropout media. 
 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis; used to 
separate proteins based on size. 
   
SH2 Src homology 2; BCR-ABL protein domain that binds phosphotyrosine-
containing polypeptide. 
   
SH3 Src homology 3; BCR-ABL protein domain that binds to target proteins 
proline rich sequences with PXXP as the binding motif.   
 
Ssp Ic domain  from Ssp DnaE (Synechocystis species, strain PCC6803, DnaE 
polymerase III alpha subunit). 
   
Taq Polymerase Synthesizes a complementary DNA strand from a single strand of DNA, 
isolated from Thermos aquaticus. 
   
Thermocylcer PCR machine or DNA amplifier, holds at different temperatures to allow 
DNA to denature, anneal, elongate. 
   
Transformation Introduction of foreign DNA into a cell. 
   
Trp1 Gene encoding phosphoribosylanthranilate isomerase, an enzyme that 
catalyzes the third step in tryptophan biosynthesis. 
   
Tyrosine Kinase An enzyme that phosphorylates tyrosine molecules in proteins.   
 
  xviii  
Ura2 Gene encoding the enzyme carbamoylphosphate synthetase - aspartate 
transcarbamylase which catalyze the first two enzymatic steps in the 
biosynthesis of pyrimidines. 
   
Ura3 Gene encoding the enzyme orotidine 5-phosphate decarboxylase, which is 
involved in the synthesis of pyrimidine ribonucleotides. 
   
Vector (or Plasmid) Used to express foreign proteins or proteins as a higher concentration than 
normal in genetically modified cells. 
   
Western blot A nitrocellulose membrane that contains protein transferred from an 
electrophoretic gel; the membrane (or blot) is probed with a labeled 
antibody that will bind specifically to the protein of interest. 
   
X-gal Used to indicate whether a bacterium expresses the β-galactosidase 
enzyme. 
   
XhoI Restriction enzyme that cuts the DNA sequence C|TCGAG between the 
first C and T, isolated from Xanthomonas campestris. 
 
Yeast two-hybrid An assay used to identify protein-protein interactions within a yeast cell. 
  
 
YPD    Yeast peptone dextrose; media for growing yeast. 
 
YPDA+  Yeast peptone dextrose with adenine added; media for growing yeast.  
 
β-galactosidase  Enzyme that hydrolyzes X-gal into galactose and 4-chloro-3-brom-indigo 
which forms a visible blue precipitate.  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Chapter 1 Introduction 
 
1.1 Background 
Antibodies are proteins produced by the immune system that bind with high specificity 
and affinity to foreign molecules. The target of an antibody is called an antigen. The ability of 
antibodies to specifically bind to their target with high affinity makes them desirable as 
therapeutic, diagnostic, and research affinity reagents (1). Therefore, the production of functional 
antibodies and techniques to isolate them against protein targets is in high demand.  
Typically, antibodies are produced by challenging a host animal with an antigen (2) or by 
screening synthetic antibody libraries for antibodies that bind a particular antigen (3). Raising 
antibodies in animals is time consuming and expensive. Single chain variable fragments (scFvs) 
can be screened for interactions using in vitro display systems such as phage, yeast surface, and 
ribosome display (4). The most common way to isolate synthetic antibodies is with phage 
display technology (3). Currently, it is not possible to express antibodies on the surface of phage 
due to their large size and folding limitations. As a result, synthetic antibody fragments 
containing parts of the antibody are used for phage display. One type of antibody fragment, 
referred to as single-chain variable fragments (scFvs), consists of the light and heavy variable 
domains of an antibody connected by a peptide linker; forming a single amino acid chain that 
ideally folds to reconstitute the binding site of a natural antibody. Despite lacking antibody 
constant regions, scFvs have extremely high affinity and specificity for their targets. This 
binding ability comes from the complementarity determining regions (CDRs). Each variable 
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domain contains three CDRs that fold to form the binding site of the scFv. CDRs are surrounded 
by constant regions that serve as a scaffold to correctly display them.  
Phage display and other display technologies have proven to be useful for isolating scFvs 
that interact with extracellular targets. ScFvs isolated against intracellular targets often do not 
express well inside of cells, or bind poorly in vivo. Poor expression may be due to the structure 
of the scFvs, which consist primarily of a β-barrel framework formed by the hydrophobic 
interaction of the two variable domains (5). The interaction between the two variable domains is 
not inherently stable, as scFvs have been shown to unfold and aggregate. The interaction 
between these two domains is enhanced by the linker peptide, which keeps the domains in close 
proximity, but aggregation is still a problem. In the cell, this instability leads to low expression 
levels and short half lives of the scFvs. 
Despite the relative instability of scFvs inside cells, there are several reports using the 
yeast two-hybrid assay as a selection assay to isolate scFvs against intracellular protein targets 
(6). The yeast two-hybrid assay is a common technique used to identify protein interactions of 
interest inside an eukaryotic cell. This serves as a technique to isolate scFvs under selective 
pressure to fold and function inside mammalian cells (7). In the yeast two-hybrid assay, two 
hybrid proteins are co-expressed from plasmids in S. cerevisiae. One hybrid protein consists of 
the target protein fused to a DNA binding domain, which binds to the promoter region of a 
reporter gene. The second hybrid protein contains a member of a protein library, in our case an 
scFv, fused to a transcription activation domain. If the target protein and a library member 
interact with each other, the transcription activation domain is brought to the promoter resulting 
in the activation of the reporter gene. The activity of the reporter gene(s) is monitored to select 
for protein interactions.  
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To bind any given protein target with high affinity, the scFv library must contain many 
members. The variable CDRs within the scFv library dictates the specificity of the individual 
scFvs. Mutating the amino acids in the CDRs results in combinatorial libraries of scFvs. On 
average there are approximately 20 positions within the CDRs that contact the target protein. 
Since there are 20 naturally occurring amino acids, a library containing every combination would 
have 2020 different members using all amino acids at each important positions within the CDRs. 
A library this large is impossible to create or screen in yeast. To overcome this problem, 
antibody fragment libraries can be created with decreased diversity by limiting the number of 
amino acids used at each position, or the number of amino acid positions mutated (8,9). To 
decrease the diversity of an antibody fragment library the amino acids varied within the CDRs 
(number of amino acids) and/or the number of variable CDRs (number of amino acid positions) 
are reduced (8,9). ScFv libraries with minimal diversity still contain high affinity binders that can 
be isolated against a range of targets. Library design is a crucial aspect in producing 
combinatorial peptide libraries because not all amino acids are specific in their interactions. 
Arginine in particular is often involved in non-specific binding (10). Where tyrosine and serine 
are usually involved in specific interactions (10) and tyrosine is primarily involved in contacting 
the antigen (8).  
Another critical point in creating scFv libraries is the stability of scFvs. The scFv 
structure and systems to express scFvs have been modified in an attempt to increase the ability of 
scFvs to fold properly within the cell. Many of these modifications modestly improve scFv 
folding; however, an optimal system for expressing scFvs in cells has not yet been developed. 
For example, fusing scFvs to stable, soluble proteins can create steric hindrance, which prevents 
proper folding of the protein (11). Cyclization of scFvs has not been reported, but generally 
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protein cyclization has been shown to increase protein stability and solubility in a number of 
different studies (12-15). Cyclization constrains the protein in a conformation where the protein 
cannot unfold and aggregate. Cyclizing scFvs should be useful in increasing their stability 
ultimately increasing their ability to remain soluble. 
 
1.2 Objectives 
The objectives of this research were to optimize scFv library design by increasing the 
stability and affinity of scFvs isolated using the yeast two-hybrid assay. To achieve this objective 
the following three variables were characterized: 
(i) CDR amino acid diversity;  
(ii) Number of CDRs containing random amino acids; and  
(iii) Cyclization of scFvs. 
 
1.3 Approach 
To investigate the effect of the three different parameters on the scFv folding and binding 
capacity in the yeast two-hybrid assay, eight different libraries were designed and generated. Six 
scFv libraries were initially produced LK3, LK4, cK4, LT3, LT4, cT4, where c is cyclic, L is 
linear, K is four amino acids, T is two amino acids, and the number following K or T is the 
number of CDRs. The six libraries were screened five times in five different yeast two-hybrid 
screens. In every screen, more scFvs were isolated from the cyclic libraries compared to the 
linear libraries. To confirm whether this trend is also observed with the K3 and T3 libraries, cK3 
and cT3 libraries were subsequently synthesized. Individual scFvs isolated from the yeast two-
hybrid screens were expressed in S. cerevisiae and E. coli to analyze the expression and to purify 
them for further analysis of cyclization. 
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1.4 Thesis Organization 
In the first section of Chapter 2, natural antibodies and scFvs are introduced and scFv 
applications are reviewed. In the second section, the three variable parameters tested in this study 
are described in detail. In the third section, the yeast two-hybrid assay is explained as well as the 
protein domains used in the assay. Chapter 3 reviews the materials and methods use in this study. 
Chapter 4 presents and describes the results found from the scFv yeast two-hybrid assays, and 
scFv protein expression and purification.  In Chapter 5, results obtained from the experiments are 
described. Chapter 6 the results are discussed with respect to the current literature and Chapter 7 
contains future recommendations for this project. 
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Chapter 2 Literature Review 
 
2.1 Natural antibodies and scFvs 
Natural antibodies are large proteins that possess many desirable properties that can be 
exploited in medicine and research. They are made up of two identical heavy chains and two 
identical light chains (Figure 2-1). Each light chain contains one variable domain and one 
constant domain. Each heavy chain contains one variable domain and on average three constant 
domains. The constant domains hold the antibody together by disulphide bonds. The variable 
domains contain three hypervariable regions called, complementarity determining regions 
(CDRs). The CDRs fold up to form loops, which bind to the antibody's target and dictate 
specificity and affinity.  
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Figure 2-1: Full length antibody, Fab fragment and Fv fragments.  
(a) The full-length antibody contains two identical light chains and two identical heavy chains. 
The antibody contains two variable light chain domains (VL), two constant light chain domains 
(CL), two variable heavy chain domains (VH) and three or four constant heavy chain domains 
(CH). The constant domains are held together and stabilized by disulphide bonds (-SS-). Each 
variable region contains three hypervariable regions called complementarity determining regions 
(CDRs). There are three CDRs on each heavy chain (H1, H3, H3) and three on each light chain 
(L1, L2, L3). (b) Fragment antigen binding (Fab) portion of an antibody. Fabs are made up of a 
VL, VH, CL and CH. (c) Single chain variable fragments (scFv) contain the CDRs of an 
antibody and are the smallest antibody fragment that retains the antibody-binding site. Figure 
adapted from (16). 
 
 
Early studies have shown that antibodies can be used to block the function of their targets 
by injecting them into a population of cells (17). Antibodies cannot be readily used to block 
intracellular targets because their structure is stabilized by disulphide bonds, which do not form 
within the reducing environment of a cell (18). As a result, it is not possible to express properly 
folded, stable antibodies within cells. Also, the large size of the antibody structure limits its 
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intracellular use and has led to the development of smaller antibody fragments for intracellular 
applications (4). 
 Antibody fragments are created using the hypervariable binding regions of the antibody 
(Figure 2-1). The single-chain variable fragment (scFv) is one of the most commonly studied 
antibody fragments (Figure 2-2).  
 
 
 
Figure 2-2: ScFv structure and CDR folding and binding model.  
(a) Single chain variable fragment (scFv) consists of a variable light chain domain (VL) and a 
variable heavy chain domain (VH). The domains are linked together by a linker peptide. Each 
domain contains three complementarity determining regions (CDR). The domains are stabilized 
by inter-domain disulphide bonds (-S-S-). (b) The CDRs of the scFv fold forming loops which 
create the binding pocket. (c) An example of how a scFv binds to its antigen through its CDRs. 
Figure adapted from (16). 
 
 
ScFvs, which are also referred to as intracellular antibodies or intrabodies, are a smaller, 
more versatile alternative to antibodies. ScFvs are made up of a heavy chain variable region and 
a light chain variable region of the natural antibody linked together by a linker peptide (Figure 2-
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2) (19). The linker peptide constrains the two variable domains within the vicinity of each other, 
which increases the effective concentration of the light and heavy chains and stabilizing the scFv 
structure (20). The flexibility of the linker favors the intra-molecular association of the two 
variable domains without obstructing their interaction with each other. The variable domains of 
the heavy and light chains are further stabilized by disulphide bonds within the variable domains. 
Each variable fragment contains three CDRs, which fold up to form loops that contact the target 
protein and dictate the binding specificity (19).  
 
2.2 Applications of scFvs 
The development of scFvs has increased the applications for antibody-like reagents. The 
intracellular use of scFvs increases their application potential compared to the full-length 
antibody. ScFvs with identical CDRs to a natural antibody bind the same targets with similar 
binding affinity (19). This means that any full-length antibody isolated against a target can be 
made more versatile by creating its scFv counterpart. This versatility expands to fields such as 
therapeutics, diagnostics and research. 
The use of scFvs in research has increased in the last few years. ScFvs are used in bio-
affinity assays to specifically purify a target protein (21). ScFv microarrays can be used to 
identify biomarkers associated with specific diseases (22). Biomarkers can be used to 
understand, identify and diagnosis disease. They can also be used as drug targets. By identifying 
potential drug targets further studies can be done to develop drugs. For example, Carlsson et al 
use scFv microarrays to create a signature protein profile for metastatic breast cancer (22). These 
types of profiles allow the identification of proteins that may be mis-regulated in a malignancy. 
The mis-regulated proteins can then be used as targets in future studies to determine their role in 
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the disease. Proteins linked to the cause of a disease can be screened against libraries of scFvs. 
ScFvs isolated against disease-associated targets can be used to cure or treat the disease. ScFvs 
with high affinity and specificity to a target protein can be used to inhibit function by disrupting 
protein-substrate, protein-protein, DNA-protein interactions, localizing the target away from site 
of action, or targeting the protein or cell to death.   
ScFvs can be used as diagnostic tools to identify potential drug targets. Protein 
microarrays can be used to identify protein-protein interactions, substrates of an enzyme, targets 
of biologically active small molecules in search of specific target proteins found in particular 
diseases (23). Protein microarrays made with scFvs are very useful because they are a high-
throughput assay that can detect very low amounts of specific proteins within a mixture that may 
not be detectable by other methods due to low concentration. Early detection of specific 
biomolecules involved in certain diseases is important because it can make the difference 
between being able to treat a disease and the spread of the disease into an untreatable state. For 
example, a fungal infection in an immuno-compromised person can be fatal, however if the fungi 
is detected early enough when the fungus has not had as much time to multiply it can be more 
successfully treated. Improvements in detection and diagnostics are also useful future predictors 
of relapses and to monitor treatments (23). The output signal of protein arrays can be 
colorimetric, fluorescence, or chemiluminescence. Colorimetric assays developed using scFvs 
contain the specific scFv tethered to a protein tracer. For example, cells being tested for rabies 
viral infection can be immobilized and incubated with a rabies specific scFv fused to alkaline 
phosphatase (24). The excess scFv-alkaline phosphatase fusion is washed away and an alkaline 
phosphatase substrate, such as p-nitrophenol phosphate can be added. If the rabies virus is 
present in the cells they will bind to the scFv-alkaline phosphatase fusion. The alkaline 
 11 
phosphatase will cleave the p-nitrophenol phosphate into p-nitrophenol, which can be monitored 
at 405 nm (24). This is a direct way to detect the presence of rabies virus.  Fluorophores fused to 
scFvs are used in a similar way (25). Chemiluminescence could be used in protein arrays; 
however, to date no studies have been reported. These diagnostic measures can be used in the 
diagnosis of many diseases. They are inexpensive, rapid and very sensitive which is useful in 
early detection of a disease. With early detection of a disease it is easier to treat. 
ScFvs have been isolated against various proteins to use in the treatment of disease. Their 
ability to penetrate tissue and bind their target is better because they are smaller than antibodies 
(26). ScFvs also clear faster from the body than larger antibody fragments making them less 
immunogenic (26). ScFvs can be used to target specific proteins or protein domains to inhibit or 
block protein function. Viral and host cell proteins causing infectious disease such as HIV-1 
have been targeted with scFvs to try and control infection, replication and spread of the HIV-1 
virus (reviewed in, (16)). ScFvs specific for oncogenes, fusion protein products and over-
expressed regulatory proteins and receptors involved in the development and spread of cancer 
have been isolated (reviewed in, (16)). Neurological diseases caused by aggregated and hyper-
phosphorylated proteins such as Huntington’s disease and Alzheimer’s have also been targeted 
by scFvs (reviewed in, (16)). Anti-sperm scFvs have been isolated with possible future 
contraceptive applications (27). ScFvs specific for a target have been fused to a toxin to target 
specific cell death or inhibit protein synthesis (28). Herceptin is a monoclonal antibody that was 
FDA approved in 1998 and is currently used as a drug to treat specific metastatic breast cancer 
(29). This is promising for the future of scFvs because monoclonal antibodies are easily made 
into the scFv format. ScFvs are easier to produce than full length antibodies and are easier to 
deliver to the site of action. There are scFvs currently in clinical trials (reviewed in, (16).  
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2.3 Considerations in scFv library design 
In order to isolate scFvs for potential drug reagents a logical approach to the design of 
scFv libraries should be considered. ScFvs contain one binding site made up of two variable 
domains (Figure 2-2). ScFv variable domains are designed after those found in a natural antibody 
where one of the variable domains is from the heavy chain and the other is from the light chain 
(Figure 2-1). Each variable domain contains three complementarity determining regions (CDRs) 
that make up the hyper-variable loops of the scFv (Figure 2-2). The variable CDRs make up the 
antigen-binding site of the scFv.  
 
2.3.1 Number of variable CDRs 
The ideal scFv library would contain all possible combinations of the twenty amino acids 
in the CDR regions. Based on the assumption that the average number of interacting residues 
within the CDRs is approximately twenty (30), a library that contains all 20 amino acids at all 
twenty positions in the CDR region would consist of 2020 possible combinations. In practice it is 
not possible to screen a scFv library this large. Phage display and the yeast two-hybrid assays 
can only generate libraries with approximately 1010 or 107 members, respectively. This leaves 
two options. The first option is to create libraries that only sparsely sample the total sequence 
space and the second option is compromise the diversity by limiting the number of variable sites 
and/or the number of different amino acids used to vary the sites.  
CDRs important in binding a target vary depending on the antibody-antigen complex 
being analyzed. For most antibody-antigen interaction complexes the heavy chain contributes 
more than the light chain in binding the antigen (31).  
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Each CDR contains a different number of amino acids that contribute to antigen binding. 
For example, CDR1 from the heavy chain (CDR H1) is approximately six amino acids long; 
however, only four amino acids usually contact the antigen (30,31,32). CDR H2 is usually 
between eight and ten amino acids long, but only approximately six of these amino acids 
participate in binding (30,31,32). CDR H3 is found in the middle of the binding pocket of almost 
all antibody constructs (32). It is the most variable CDR in terms of size, conformation, and 
amino acid composition (32). CDR H3 is also the most important in determining antibody 
specificity (32). CDR H3 is usually between seven and nine amino acids in length and all of 
these amino acids have been shown to be important in antibody-antigen interactions (30,31,32). 
Light chain CDRs that contribute to antigen binding vary amongst different antibody-antigen 
complexes. In general, CDR L3 contributes the most to antigen interactions, whereas CDR L2 
contributes the least with sometimes only two residues contributing to the antigen interaction 
(31). 
  
2.3.2 Varied amino acids within the CDRs 
An scFv library with all twenty amino acids varying the CDRs is too large to create and 
screen in yeast. Previous studies have shown that minimal libraries can be produced by varying 
the CDRs with only a few amino acids (32). These minimal libraries with reduced diversity are 
able to generate highly specific interactions. 
Degenerate codons are used to create random regions (ie CDRs) to generate large and 
diverse synthetic scFv libraries. These libraries can be used to isolate scFvs that interact 
specifically with a chosen protein target. Several research groups examined the amino acid 
composition of antibody CDRs and found that tyrosine occurs in the CDRs of antibodies in an 
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unusually high abundance (31,33-35). Based on these results another research group generated 
high affinity fragment antigen binding (Fab) libraries with a minimal number of amino acids 
within the variable regions (8). Fabs are another type of antibody fragment that are larger than 
scFvs (36). ScFvs consist of the variable domains from the heavy and light chain, whereas Fabs 
contain the variable domain and a constant domain from the heavy and light chain (36) (Figure 
2-1).  Eleven libraries diversified with four amino acids were created and screened against four 
different proteins (8). Using these minimal amino acid diversity libraries, high affinity Fabs were 
isolated specific for the targets screened against (8). Some of the Fabs contain binding constants 
(Kd) with single digit nanomolar affinity for their protein target (8). The library with the largest 
binding capacity contains CDRs varied with tyrosine, serine, alanine, and aspartate. Tyrosine and 
serine are present in the CDRs of the three of the eleven libraries that interact with the highest 
number of proteins (8).  
Structural analysis of the binding residues of the Fabs reveal that tyrosine side chains are 
responsible for mediating most of the antigen recognition (8). The explanation for this 
phenomenon is that tyrosine has hydrophobic and hydrophilic characteristics allows it to interact 
with the target in multiple ways and to be accommodated in most environments. These properties 
enable tyrosine to make highly specific and affinitive contacts with antigen (8). Serine and 
alanine allow for space and conformational flexibility to facilitate productive contacts between 
tyrosine and the target protein (8). Large amino acids like tyrosine and tryptophan function well 
adjacent to smaller amino acids like serine and alanine since they provide space for free rotation, 
whereas large amino acids next to tyrosine and tryptophan prevent flexibility through steric 
hindrance (30).  
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Structural characterization of the Fab-antigen complex reveals that the interaction 
involves all three heavy chain CDRs; the light chain CDRs contribute minimally to antigen 
binding (9). The small amino acids have little direct contact with the antigen and instead aid in 
positioning tyrosine for antigen binding. Based on these results, Fellouse et al. constructed a 
library in which the CDR regions were randomized using only tyrosine and serine (9). One of 
their Fab libraries varied at ~ 25 positions in only the heavy chain CDRs. With this library, Fabs 
against a broad range of targets are isolated. This study shows that a Fab library with only 
tyrosine and serine diversifying the CDRs is sufficient to mediate highly specific antigen 
recognition (9). Design of these minimal amino acid diversity libraries can be applied to other 
antibody fragments like scFvs. The goal behind creating such low diversity libraries is to isolate 
an scFv specific for a target protein. The scFvs can be further improved using affinity maturation 
to increase binding affinity and obtain a high affinity scFv that can be later used in therapeutics, 
diagnostics, or research.  
 
2.4 Stability Limitations in ScFv Expression 
Designing combinatorial diversity of scFv CDRs is crucial for creating scFv libraries that 
contain high affinity binders with a reasonable library size. If an scFv is not stably expressed it is 
not functional; therefore the final diversity of the library is also limited by the expression and 
solubility of scFvs. The variable heavy and light chain domains are internally stabilized by intra-
domain disulphide bonds (Figure 2-2), which are not supported in the reducing environment of 
the cell (37). These disulfide bonds are highly conserved in all antibodies and stabilize the scFv 
by connecting the β–sheets of the domains (37). ScFvs are also stabilized by hydrophobic 
interactions between their domains (5). These inter-domain hydrophobic interactions between the 
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VL and VH domains are not sufficient to keep the two domains stably associated (38). Low 
stability of the VH-VL complex leads to dissociation or ‘opening’ between the scFv domains, 
exposing hydrophobic β–sheet residues resulting in inter-molecular associations and aggregation 
of scFv (Figure 2-3) (39,40). For example, the heavy chain variable domain of one scFv will pair 
with the light chain variable domain of a different scFv (41). 
 
 
 
Figure 2-3: ScFv structure and aggregation.  
(a) Structure of a properly folded scFv. (b) Aggregated scFvs where the heavy chain of one scFv 
is interacting with the light chain of a different scFv. Aggregated scFvs are not soluble. 
 
 
 Many different approaches have been attempted to stabilize the scFv structure to prevent 
aggregation and induce proper folding. Some of these approaches include varying the linker 
length and composition (42), random mutagenesis of the scaffold and CDRs (5), adding fusion 
proteins (43), disrupting the hydrophobic patches at the scFv interface (44), mutating the scFv 
framework (45,46) and co-expressing chaperones (47). Although these attempts to stabilize the 
scFv structure show improvements in scFv stability they introduce new problems. For example, 
the formation of dimers or trimers occurs with shorter linker length (48) and steric hindrance 
prevents proper folding in the presence of some fusion proteins (11). 
To be expressed inside a cell, an scFv needs to be able to fold stably in the absence of 
disulfide bonds and avoid aggregation (49). Selection strategies have been developed in an 
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attempt to isolate antibody fragments with enhanced stability. Generally this involves mutating a 
single antibody against a known target and screening for mutations with enhanced stability 
(37,50). Producing scFvs using this method leads to a predetermined stable scFv framework that 
limits the user to diversifying only specific CDR positions in fear of disrupting stability. Specific 
framework amino acids have been shown to stabilize the scFv variable domains in a few 
different scFvs; however, these specific residues are not sufficient to successfully express and 
isolate most scFvs in the cytoplasm (5). The amino acids within the variable region of the CDRs 
contribute to its successful intracellular folding. Certain amino acids can potentially have a 
negative effect on proper scFv folding. 
The proper folding of scFvs can be detected by specific bacterial proteins, which have 
specificity for antibody framework regions. For example, Protein L from Peptostreptococcus 
magnus binds to most κ-light chains from antibodies (51,52). Protein A from Staphylococcus 
aureus binds to the heavy chain of some antibodies. ScFvs have been successfully purified using 
both protein A and protein L (53). The binding of an scFv to protein A or protein L is a way to 
detect and purify properly folded scFvs.  
 
2.5 Inteins and protein cyclization 
Cyclizing a protein can increase its stability and solubility (12,14,15). Proteins can be 
cyclized within cells using a split-intein (54,55). Inteins are self-splicing protein domains that are 
removed during posttranslational processing (Figure 2-4) (56). Amino acid residues within the 
extein, adjacent to the splice site and internal residues within the intein control the splicing 
reactions. Once the intein is spliced out of the protein the flanking proteins (exteins) are joined 
 18 
by a peptide bond producing the mature protein. Inteins have been found to splice proteins in cis 
as well as in trans (57). 
 
 
 
Figure 2-4: cis and trans splicing of inteins.  
(a) cis splicing intein; the N terminal and C terminal domains of the intein are joined together 
and are flanked by the extein sequence to be joined. The intein domains perform the self-excising 
reaction and are removed from the protein joining the two-extein domains by a peptide bond. (b) 
trans-splicing split-intein; the intein domains are expressed separately with an extein domain. 
The intein domains catalyze a self-splicing reaction and are excised out of the protein ultimately 
joining the exteins by a peptide bond. 
 
 
Trans-splicing allows inteins to be manipulated to cyclize proteins (Figure 2-5). A protein 
can be cyclized by fusing it between the intein domains with the C-intein domain on the N-
terminal end of the protein and the N-Intein domain on the C-terminal end of the protein. The 
(a)
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intein domains catalyze the natural reactions joining the two ends of the extein together 
ultimately cyclizing the protein.  
 
 
 
Figure 2-5: Intein mediated protein cyclization.  
The protein to be cyclized is place in between the two-intein domains with the N-intein domain 
and C-intein domain swapped. The intein domains catalyze the self-splicing reaction cyclizing 
the protein. 
 
 
The split intein dnaE from Synechocystis sp. (Ssp) can be used to cyclize proteins in vivo 
(54). The cyclization of dihydrofolate reductase increases its in vitro thermostability and 
prevents amino-terminal modification and proteolysis (54). Cyclizing the tyrosinase inhibitor 
pseudostellarin F dramatically increases the amount isolated (54). A different trans-splicing 
intein dnaE from Nostoc punctiforme (Npu) can be used to cyclize proteins. Previous studies 
show that the Npu intein is quite tolerant to the amino acid compositions within the target extein 
(58). Also, the C-intein and N-intein domains from the Npu and Ssp inteins can be swapped and 
spliced with >98% efficiency. By using the Npu N-intein and Ssp C-intein the splicing is more 
tolerant to different amino acid substitutions within the extein sequence than the Npu intein (58). 
Precursor Protein C-Intein Linear Protein N-Intein
C-InteinN-Intein
Protein trans-splicing 
Cyclized Protein
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The hybrid Ssp-Npu intein is more useful since it allows more change in all potential proteins to 
be cyclized. 
A recent study shows that the cyclization of two proteins with a split intein stabilizes a 
binary complex (59). These results provide strong evidence suggesting that cyclization can be 
used to stabilize scFvs. ScFvs can be constructed in the VH-linker-VL (60) or the VL-linker-VH 
(61) orientation, which shows that no structural barriers exist concerning the construction of 
cyclic scFvs (12,14). 
 
2.6 Screening combinatorial scFv libraries 
Isolating functional scFvs is a major problem preventing their use. Many strategies aim to 
optimize the scFv framework for expression inside the cell; however, it is not clear whether there 
is a general framework that can support diverse CDRs while retaining intracellular stability. 
Universal scFv frameworks with randomized CDRs have been used to isolate intracellular scFvs 
(62). ScFvs can be screened for interactions using in vitro display systems such as phage, yeast 
surface, and ribosome display (4). Phage display is one of the more popular strategies for 
obtaining intracellular scFvs from a library (6,49,63,64). In phage display the library of scFvs are 
expressed on the outside of phage by fusion to the phage protein coat. As a result, scFvs isolated 
by phage display are not optimized for expression inside cells. This technique is limited by the 
lack of selection pressure for selected antibody fragments to function inside cells. As a result, 
most of the antibody fragments isolated are not stable and have low expression levels and short 
half-lives when expressed intracellularly. Recently, Villani et al isolated a few scFvs from a 
library using phage display under reducing conditions, removing any disulphide bonds to 
increase the chance of the scFvs being stable inside cells (65). ScFvs isolated under reducing 
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conditions (isolated from bacterial cytoplasm or reduced with DTT) bound to their target with 
comparable affinity to the scFv in its oxidized state, however, the scFvs could not be isolated 
with protein L (which is an indicator of correct folding) suggesting that the scFvs were not 
properly folded or possibly did not need to be properly folded to bind to their target (65). Also, 
the binding ability was not tested within the environment of a cell, which is a different 
environment containing obstacles that can prevent the scFv from binding its target (65).  
The yeast two-hybrid (Y2H) assay is used to isolate protein interactions within the 
environment of a eukaryotic cell (66). A mixture of variable scFvs is cloned into Y2H expression 
vectors, creating a large diverse combinatorial scFv library expressed in yeast (49). Each scFv 
library member is expressed inside a different yeast cell. A target protein is expressed in the 
opposite yeast cell mating type from the library (Figure 2-6) (66). ScFv library cells are mated 
with the cells expressing the target protein, which produces diploid cells. Each diploid cell 
contains an scFv from the library and the target protein or protein domain. The selection for 
diploid cells containing an interacting library member and protein domain can be screened for 
using reporter genes. Reporter genes used in the Y2H are located downstream from a DNA 
binding domain (66). The target protein domain is tethered to a DNA binding domain. For 
example, LexA (a DNA binding protein) will bind to its binding site on the DNA, holding the 
target domain near the promoter of the reporter gene. The scFv or library member is tethered to a 
transcription activation domain (66). If the scFv library member within the diploid cell interacts 
with the protein domain the activation domain will activate transcription of the reporter gene. A 
reporter gene expresses a phenotype that can be observed through cell growth or phenotype.  
The Y2H assay is a system that can be used to find an scFv that binds to a protein target 
of interest, which will select against scFvs that are not expressed or do not fold properly in the 
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intracellular environment. The Y2H assay still needs to be improved in order to increase the 
number of library members that can be successfully expressed and screened in the Y2H assay 
and to decrease the number of false positives. 
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Figure 2-6: ScFv yeast two-hybrid assay.  
(a) Without any proteins near the transcription start site there is no transcription initiation. (b) 
The target protein fused to the LexA DNA binding domain near the transcription start site alone 
will not initiate transcription. (c) The scFv fused to the activation domain (AD) alone will not 
activate transcription. (d) If the scFv fusion and target protein do not interact transcription will 
not be initiated. (e) In the presence of a scFv and target protein that interact transcription of the 
reporter gene is initiated and the reporter gene is expressed.  
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Chapter 3 Materials and Methods 
 
3.1 Microorganisms and Media 
Media components and chemicals were obtained from VWR (Canada) unless otherwise 
noted. Oligonucleotides were obtained from Integrated DNA technologies (IDT, USA) (Table 3-
1). 
 
3.1.1 S. cerevisiae Strains 
S. cerevisiae strains used in this study include EY111 and EY93. The general 
characteristics of the strains are listed below: 
EY111 – MATα his3 trp1 ura3::LexA8op-lacZ ade2::URA3-Lex8op-ADE2 
leu2::LexA6op-LEU2* derived from EGY48 (67) 
EY93 – MATa ura2 his3 trp1 leu2 ade2::URA3 is derived from EGY42 (68)  
*Explanation in Glossary section under :: 
Standard procedures were used for culturing S. cerevisiae as outlined in Geyer et al. (69). 
YPD media consisted of 1% (w/v) yeast extract, 2% (w/v) peptone, 2% (v/v) dextrose; synthetic 
dropout media (SD): 0.67% (w/v) yeast nitrogen base without amino acids, appropriate amino 
acid dropout, supplemented with either 2% (v/v) dextrose or 2% (v/v) galactose and 1% (v/v) 
raffinose. All solid media also contained 2% (w/v) agar. For blue/white screening in S. cerevisiae 
80 µg/mL of X-gal (Invitrogen, Canada) was added to medium. 
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Table 3-1: Oligonucleotides used in this study.  
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Table 3-1 (continued) 
 
*The name of the oligonucleotide is indicated in the first column. The length of the 
oligonucleotide in base pairs (bp) is shown in the second column. The sequence is shown in the 
third column in bases listed from the 5 prime (‘) to the 3 prime (’) end. The organism that the 
oligonucleotide was used to clone into is indicated in the second last column. The use and type of 
primer is also shown. 
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3.1.2 E. coli 
E. coli strains used in this study include ER2925 (New England Biolabs, Canada),  BL21 
codon plus (Stratagene, Canada), and XL1Blues (Stratagene). Standard procedures were used for 
culturing E. coli as outlined in (70-72). The LB medium consisted of 1% Tryptone, 0.5% yeast 
extract, 85.6 mM NaCl, and 1 mM NaOH. For E. coli vector selection kanamycin and ampicillin 
were used at concentrations of 0.05 µg/mL and 0.1 µg/mL respectively when applicable. The 
solid medium contained 2% (w/v) agar.    
 
3.1.3 Vectors 
Vectors used in this study include pEG202 (Figure 3-12) (67), pET28b (Figure 3-13) 
(Novagen, Canada) and pIL500 (67) (Figure 3-3). pIL500 was supplied by Kris Barreto, a 
graduate student in Dr. Geyer’s lab. The pIL500 plasmid was derived from pJG4-5. A 
kanamycin gene was cloned in. The Ssp-Npu intein machinery was cloned in between the XhoI 
and EcoRI restriction sites flanking an NruI endonuclease restriction site.  
 
3.2 Primer design for yeast amplification and CDR construction 
All forward yeast amplification primers were designed by taking 39 base pairs 
immediately before the clone site from the vector sequence and 20 base pairs from the beginning 
of the DNA insert. All reverse yeast amplification primers were designed by taking 39 base pairs 
immediately after the clone site from the vector sequence and 20 base pairs from the end of the 
DNA insert. 
The CDR construction primers are more variable in composition and construction 
because they contain degenerate codons. For CDR H1 primers, 20 base pairs were taken from the 
scFv framework immediately before the NruI restriction site followed by 18 base pairs 
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comprising 6 degenerate codons followed by 48 base pairs to create the majority of framework 2 
(FR2) sequence between CDR H1 and CDR H2 (Figure 3-7).  
The CDR H2 primer contained 20 base pairs from the end of FR2, 30 base pairs 
comprising five degenerate codons followed by 23 base pairs from the scFv immediately after 
the NruI restriction site.  
The CDR H3 site was made from 20 base pairs from the scFv framework immediately 
before the XhoI site, 21 base pairs comprising seven degenerate codons followed by 20 base 
pairs from the scFv framework immediately after the XhoI site. 
The forward E. coli amplification primers were created by taking the first nine base pairs 
from pET28b immediately after the XhoI site and the last 17 or 18 base pairs from the beginning 
of the scFv or IC domain depending if protein was linear or cyclic respectively. The first nine 
base pairs include two extra base pairs in front of the EcoRI site and one extra base after to 
ensure the insert will be cloned in-frame.  
The reverse E. coli amplification primers were created from 13 base pairs from pET28b 
before the EcoRI site and 17 base pairs from the end of the scFv or IN domain depending on if 
the protein was linear or cyclic. The 13 base pair region includes three or four extra bases before 
the XhoI site, the XhoI site and 1-3 base pairs after the site to ensure the scFv is in the correct 
reading frame.  
 
 
3.3 Construction of ScFv and ScFv Library Design  
3.3.1 ScFv Framework Gene Construction 
A synthetic gene encoding the scFv framework (Figure 3-1) was constructed using 
codons optimized for expression in S. cerevisiae. Amino acid sequences of the heavy and light 
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chain were designed based on scFvs previously reported by Tanka et al (8,73,74). The region 
spanning the first and second CDR of the heavy chain was replaced with an NruI endonuclease 
restriction site to allow cloning in of random amino acids comprising CDR H1 and CDR H2 of 
the heavy chain (Figure 3-2). CDR H3, the third CDR on the heavy chain was replaced by a XhoI 
restriction endonuclease site. The light chain CDRs were fixed based on an anti-β-galactosidase 
scFv reported by Martineau et al (45). 
The program GeneDesign (75) was used to design the eighteen overlapping 
oligonucleotides (Table 3-1) that were used to construct the synthetic scFv framework gene. The 
eighteen oligonucleotides (Oligo1-Ab to Oligo18-Ab) were mixed together (0.2 ng/μL of each) 
with 1X Platinum HIFI taq polymerase buffer (60 mM Tris-SO4 (pH 8.9), 18 mM (NH4)2SO4 
(Invitrogen), 0.2 mM dNTPs, 2 mM MgSO4, and 1.0 unit Platinum HIFI taq polymerase 
(Invitrogen). The reaction mixture was placed in a thermocycler under the following conditions: 
94 °C for 2 minutes, [94 °C for 30 seconds, 56 °C for 30 seconds, 68 °C for 1 minute](30 
cycles), and 68 °C for 10 minutes. The full-length gene product was amplified in a second PCR 
reaction (Figure 3-1) where two microlitres of PCR #1 was mixed with 0.2 μM Ab-pJG4-5.Fwd 
primer (#19 Table 3-1) and 0.2 μM of Ab-pJG4-5.Rvs primer (#20 Table 3-1) using the 
conditions described above. 
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Figure 3-1: ScFv Framework Gene Construction.  
The scFv framework was created using eighteen overlapping oligonucleotides, which were 
amplified in PCR reaction #1. The scFv scaffold was PCR amplified in PCR reaction #2 using 
primers with complementarity to pIL500 (….). The amplified scFv scaffold was cloned into 
pIL500. The numbers indicate the primer used at each step and are shown in Table 3-1. 
 
 
The scFv framework heavy chain sequence contains a NruI site (in place of CDRH1, 
framework 2 (FR2) and CDR H2) flanked by framework 1 (FR1) and framework 3 (FR3) 
(Figure 3-2). A XhoI site (in place of CDR H3) flanked by FR3 and framework 4 (FR4). A linker 
peptide fuses the heavy chain to the light chain. 
 
 
 
 
Figure 3-2: ScFv Framework.   
The scFv framework is an incomplete scFv. The CDR H1, FR2, and CDR H2 have been replaced 
by a NruI restriction site. The CDR H3 has been replaced with a XhoI site. The light chain CDRs 
are in place but they are not variable. The black segments represent the framework sequences 
(FR). The thin line indicates the linker peptide and the grey segments show the light chain CDRs. 
!"#$%%&
!"#$%%&
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3.3.2 Cloning the ScFv Framework into Yeast Expression Vector 
pIL500 (Figure 3-3) was isolated from E. coli using QIAprep Spin Miniprep kit (Qiagen, 
Canada) according to the manufacturer’s instructions. pIL500 was  digested with 0.5 units of 
EcoRI endonuclease (New England Biolabs), 0.5 units of XhoI endonuclease (Fermentas, 
Canada) and 1X y+/Tango buffer (Fermentas) in a 20 µL reaction volume. The reaction was 
incubated at 37 °C overnight. The PCR amplified scFv framework was cloned into the EcoRI 
and XhoI digested pIL500 (Figure 3-4) using homologous recombination by co-transformation 
into yeast strain EY93 as described by Schiestl et al (76). 
 
 
 
 
Figure 3-3: Yeast Protein Expression Vector pIL500.   
pIL500 contains a galactose inducible promoter (GAL promoter),  an alcohol dehydrogenase 
terminator (ADH Ter) and a 2 micron origin of replication (2 μ ori). The fusion cassette consists 
of a nuclear localization signal, which localizes the expressed protein to the nucleus, a B42 
activation domain, which can activate transcription in the yeast two-hybrid system, and a 
hemagglutin or HA tag which can be used to purify the expressed protein. pIL500 contains an IC 
and IN domain from the Ssp-Npu intein which catalyzes the cyclization. Linear proteins cloned 
into the EcoRI and XhoI restriction sites will remove the intein machinery and will be expressed 
linearly. pIL500 contains the first gene involved in tryptophan synthesis (TRP1) allowing cells 
containing this plasmid to grow on media lacking tryptophan. It also contains a gene for 
kanamycin resistance allowing cells containing this plasmid to grow in media containing 
kanamycin. 
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Figure 3-4: Linear scFv (framework) cloned into pIL500.  
This figure depicts the scFv framework and full size scFv. They will look almost the same 
cloned into pIL500 with the exception that the full size scFv will be a little larger because it will 
contain all three heavy chain CDRs. The scFv (framework) is cloned into the restriction site 
EcoRI and XhoI. When pIL500 is digested with EcoRI and XhoI, the NruI restriction site as well 
as the Ssp-Npu split intein machinery for protein cyclization will be removed (Figure 3-3). This 
plasmid contains the same promoter, terminator, fusion cassette and markers as pIL500.  
 
 
 
3.3.3 CDR Library Oligonucleotides 
The scFv CDRs were created by amplifying degenerate oligonucleotides. The degenerate 
oligonucleotides were cloned into the scFv framework using homologous recombination (76). 
Combinatorial libraries consisting of two amino acids, Tyrosine (TAT codon) and Serine (TCT 
codon) are referred to as the “T” libraries. The two amino acid libraries or T libraries were 
constructed using TMT degenerate codons, where T = thymine and M = adenine or cytosine. The 
T libraries were designated as T3 or T4 depending on the number of CDRs varied within the 
structure (Table 3-2). The T3 libraries have heavy chains CDR H1, CDR H2, and CDR H3 
varied with either tyrosine or serine (Figure 3-5).  
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Figure 3-5: Positions of diversified complementarity determining regions (CDRs).  
The names of the CDRs are listed above the tables and the positions are labeled with numbers 
corresponding to Kabat (77). The heavy chain positions will be varied in all the libraries. The 
light chain positions will be varied in some libraries. The letters under the numbers refer to the 
amino acid in that position in single letter amino acid code. X denotes the variable positions.  
 
 
The T4 libraries have heavy chains CDR H1, CDR H2, CDR H3 and light chain CDR L3 
varied with either serine or tyrosine. Cyclic and linear versions of T3 and T4 were created; to 
distinguish between them they are referred to as cT3 and cT4 for cyclic.  
Table 3-2: Explanation of the library names.  
 
*The name of each library contains information that represents the configuration, the number of 
CDRs varied, and the number of amino acids used to vary the CDRs. The configuration is 
represented in the library name by ‘C’ for cyclic or ‘L’ for linear The number of amino acids 
used to vary the CDRs is represented in the library name by T or K; ‘T’ represents two amino 
acids and ‘K’ represents four amino acids. The number of CDRs that were varied is represented 
in the library name as ‘3’ or ‘4’. The CDRs that were varied are indicated in the third column, 
where H represents heavy chain, L3 represents light; chain CDR 3. 
CDR-H1
XXXXIX
3
3
3
2
3
1
3
0
2
9
2
8
CDR-H2
XTXGXXPXIX
5
8
5
7
5
6
5
5
5
4
5
3
5
2
a
5
2
5
1
5
0
CDR-H3
XXXXXXX
1
0
0
a
1
0
0
9
9
9
8
9
7
9
6
9
5
CDR-L3
XPXXXXQ
9
6
9
5
9
4
9
3
9
2
9
1
9
0
Library Name Amino Acids CDRs Varied Configuration
LT3 Tyrosine, Serine H1, H2, H3 Linear
cT3 Tyrosine, Serine H1, H2, H3 Cyclic
LT4 Tyrosine, Serine H1, H2, H3, L3 Linear
cT4 Tyrosine, Serine H1, H2, H3, L3 Cyclic
LK3 Tyrosine, Serine, Alanine, Aspartate H1, H2, H3 Linear
cK3 Tyrosine, Serine, Alanine, Aspartate H1, H2, H3 Cyclic
LK4 Tyrosine, Serine, Alanine, Aspartate H1, H2, H3, L3 Linear
cK4 Tyrosine, Serine, Alanine, Aspartate H1, H2, H3, L3 Cyclic
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Combinatorial libraries consisting of amino acids tyrosine (TAT codon), serine (TCT 
codon), aspartate (GAT codon), and alanine (GCT) were referred to as the “K” libraries. The K 
libraries were designated as K3 or K4 depending on the number of CDRs varied within the scFv 
structure (Table 3-2). The K3 libraries have heavy chains CDR H1, CDR H2, and CDR H3 
varied with tyrosine, serine, aspartate, or alanine (Figure 3-5). The K4 libraries have heavy 
chains CDR H1, CDR H2, CDR H3 and light chain CDR L3 varied with serine, tyrosine, 
aspartate or alanine. Cyclized and linear scFv library versions of both K3 and K4 were created; 
to distinguish between them, they are referred to as cK3 or cK4 for cyclic, and LK3 or LK4 for 
linear (Table 3-2). 
CDRs containing degenerate oligonucleotides were constructed in the following reaction: 
0.2 mM dNTPs, 1X PCR Buffer, 2 units of HiFi Taq polymerase. The template DNA was 
constructed and amplified using the primers indicated in Table 3-3. The reaction mixture was 
incubated in a thermocycler at 95 °C for 1 minute, [95 °C for 30 seconds, 52 °C for 30 seconds, 
68 °C for 30 seconds] (30 cycles). 
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Table 3-3: Primers used in the construction of the CDRs.  
 
*DNA sequences of primers are shown in Table 3-1. The CDRs being referred to are listed in the 
first column, K indicates that it is from the four amino acid library and T indicates it is from the 
two amino acid library; H1, H2 and H3 represent CDR 1, 2, or 3 from the heavy chain. The 
oligonucleotides or primers used are listed in the second column Primer concentration indicates 
the micromolar (μM) concentration of the oligonucleotides used in the total reaction mix. 
 
 
 
3.3.4 Cloning Degenerate Heavy Chain CDR H3 into ScFv Framework 
The degenerate CDR H3 was PCR amplified as described above (Table 3-1, Table 3-3) 
The scFv framework in pIL500 was digested with XhoI in a 100 µL reaction consisting of 1X 
NEBuffer 2 (New England Biolabs), 90 µL of scFv framework in pIL500, and 1 unit of XhoI. 
The reaction was incubated for 24 hours at 37 °C. The digested scFv framework in pIL500 was 
gel purified in a 0.5% agarose gel using a QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s instructions. The degenerate CDR H3 regions for the K and T libraries were 
cloned into the scFv framework in pIL500 using the lithium acetate transformation protocol 
(Figure 3-6) (76). 
CDRs Primers Used* Primer
Concentration (µM)
T, H1 and H2 Oligo-CDR1TMT 0.02
Oligo-CDR2TMT 0.02
CDR1-FR2-CDR2.FWD 0.2
CDR1-FR2-CDR2.RVS 0.2
K, H1 and H2 Oligo-CDR1KMT 0.02
Oligo-CDR2KMT 0.02
CDR1-FR2-CDR2.FWD 0.2
CDRR1-F2-CDR2.RVS 0.2
K, H3 KMT CDR3 0.2
CDR3.FWD 1
CDR3.RVS 1
T, H3 TMT CDR3 0.2
CDR3.FWD 1
CDR3.RVS 1
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Figure 3-6: Cloning CDR H3 into the scFv framework.  
The scFv framework refers to an incomplete scFv framework with the CDRs of the heavy chain 
and framework 2 (FR2) replaced with two restriction sites. CDR H3 was replaced with a XhoI 
restriction site. To clone CDR H3 into the scFv framework in pIL500, the plasmid was digested 
with XhoI. The CDR H3 was PCR amplified with degenerate codons to create seven variable 
regions. The amplified CDR H3 was cloned into the scFv framework in pI500 using yeast 
homologous recombination. FR stands for framework, H stands for heavy chain, and L 
represents light chain. 
 
 
 
 
In addition to the CDR H3 created in the PCR reaction, the scFv framework contains 
thirteen amino acids from the ß-galactosidase scFv CDR H3 (73) (Figure 3-7). Human CDR H3 
sequences are typically 15 to 20 amino acids long (33). This part of the CDR H3 was included to 
mimic the average size of the human CDR H3 without increasing the diversity of the library. 
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Figure 3-7: Location of ß-galactosidase scFv CDR H3. 
The scFv framework sequence includes thirteen amino acids from the ß-galactosidase scFv CDR 
H3 (73). The location of the additional sequence is shown in red. FR stands for framework, H 
stands for heavy chain, and L represents light chain. 
 
 
3.3.5 Cloning Degenerate Heavy chain CDR H1 and CDR H2 
To clone degenerate CDR H1 and CDR H2 into the scFv framework containing CDR H3 
in pIL500 the CDR H1 and CDR H2 regions were PCR amplified using the PCR reaction 
described above (Table 3-2, Table 3-3). The scFv framework (+ CDR H3) in pIL500 was 
digested with NruI (New England Biolabs) in a 100 µL reaction volume consisting of 1X 
NEBuffer 3 (New England Biolabs), 90 µL of the scFv framework (+ CDR H3) in pIL500, and 1 
unit of NruI restriction endonuclease. The reaction was incubated at 37 °C for 24 hours. The 
digested plasmid was gel purified in a 0.5% agarose gel with QIAquick Gel Extraction Kit 
according to manufacturer’s instructions. CDRs H1 and H2 were cloned in using the lithium 
acetate transformation (Figure 3-8) (76), giving rise to K3 and T3 libraries.  
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Figure 3-8: Cloning in CDR H1, FR2, and CDR H2. 
The scFv framework (+ CDR H3) refers to an incomplete scFv framework, which contains a 
NruI site in place of the CDR H1, FR2, CDR H2. To clone the insert DNA, CDR H1, FR2 and 
CDR H2 into the scFv framework (+ CDR H3) the framework in pIL500 was digested with NruI. 
The insert DNA was PCR amplified and cloned in using homologous recombination in yeast. FR 
stands for framework, H stands for heavy chain, and L represents light chain. 
 
 
 
3.3.5 Mutating Light chain CDR L3 in ScFv 
To introduce variation at the light chain CDR L3 into the K3 and T3 libraries, a 
degenerate oligonucleotide was used as a PCR primer (Table 3-3) to amplify the entire scFv 
framework in pIL500 containing degenerate CDRs H1-3 (Figure 3-9).  The following PCR 
reaction conditions were used: 1X PCR Buffer (50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM 
MgCl2), 0.2 mM dNTPs, 1 μL scFv framework in pIL500 (K3 or T3), 0.6 μM P1 pJG4-5 chK 
(#35 Table 3-1), 0.2 μM TMT (or KMT)L3.RVS (#31 and #32 Table 3-1), 0.2 μM 
Ab33.pJG26.RVS (#33 Table 3-1), 0.2 μM pJG4-5.RVS (#34 Table 3-1), 1 μL Taq polymerase 
(78). The reaction mixture was subjected to a thermocycler under the following conditions: 95 
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°C for 2 minutes, [95 °C for 30 seconds, 55 °C for 30 second, 72 °C for 30 seconds] (30 cycles), 
and 72 °C for 10 minutes. The PCR product was cloned into pIL500 digested with EcoRI and 
XhoI using lithium acetate transformation (76) giving rise to plasmids expressing K4 and T4 
libraries 
 
 
 
Figure 3-9: Mutational PCR of light chain CDR L3.   
The libraries that have four diversified CDRs were derived from the libraries with three 
diversified CDRs. The libraries with three variable heavy chain CDRs were PCR amplified with 
a mutational primer containing degenerate codons to diversify the CDR L3. Three different 
reverse primers were used to obtain enough complementarity to clone the PCR back into pIL500 
(….). The primers are represented by the bold arrows and the numbers located under the bold 
arrows indicates the primers used. The diversified CDR L3 is indicated in yellow. The 
diversified heavy chain CDRs are indicated in green. 
 
 
3.3.6 Cyclization of the ScFv Library 
pIL500 was digested with 1 unit of NruI and 1X NEBuffer 2 in a 100 µL reaction. The 
reaction was incubated at 37 ˚C for 24 hours. Plasmids expressing complete libraries with 
diversified heavy chain CDRs H1-3 (LT3 and LK3) and diversified light chain CDR L3 (LT4 
and LK4) were PCR amplified in two PCR reactions with primers containing overlapping 
complementary sequences to the Ssp-Npu split intein (Figure 3-10). In the first PCR reaction the 
primers were used to add the IC domain to the beginning of the scFv library and a second linker 
!"#$%%&
!"#$%%&
'$&
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to aid in cyclization. The following 100 μL PCR reaction was used: 1 X PCR Buffer, 0.2 mM 
dNTPs, 1 μL T3, T4, K3, or K4 scFv library plasmid, 0.2 μM P1 IntraVH3-74/pIL500 (#36 
Table 3-1), 0.2 μM P2 IntraL19/Linker (#37 Table 3-1), and 1 μL Taq polymerase. The PCR 
reaction was amplified in a thermocycler under the following conditions: 95 °C for 2 minutes, 
[95 °C for 30 seconds, 50 °C for 30 seconds, 72 °C for 2 minute] (30 cycles), and 72 °C for 7 
minutes. The second PCR reaction was used to add the IN domain to the end of the second linker.  
 
 
 
Figure 3-10: PCR amplification to cyclize the scFv libraries.  
All the scFv libraries were PCR amplified in two different PCR reactions. In the first reaction, a 
region complementary to the IC domain, as well as a second linker were added to the end of the 
light chain. In the second a region complementary to the IN domain was added. The IC and IN 
domains will catalyze a cyclization reaction, which will cyclize the scFv with the second linker. 
 
 
 
The scFv libraries were cloned into the NruI restriction site of pIL500 between the Ssp-
Npu split intein to allow for protein cyclization. The following 100 μL PCR reaction was used: 
!"#$%&'('
)*'
)*'
+,' +-'
+,'
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1X PCR Buffer, 0.2 mM dNTPs, 1 μL LT3, LT4, LK3, or LK4 scFv library plasmid, 0.2 μM P1 
IntraVH3-74/pIL500 (#36 Table 3-1), 0.2 μM P2 Linker/pIL500 (#38 Table 3-1), and 1 μL Taq 
polymerase. The PCR reaction was amplified in a thermocycler under the following conditions: 
95 °C for 2 minutes, [95 °C for 30 seconds, 50 °C for 30 seconds, 72 °C for 2 minute] (30 
cycles), and 72 °C for 7 minutes. The PCR product was cloned into pIL500 digested with NruI 
using the lithium acetate transformation in yeast (Figure 3-11) (76). This gives rise to the cT3, 
cT4, cK3, and cK4 libraries. Fifty members from each library were sent to NRC-PBI to be 
sequenced to determine the percent of functional scFvs and to confirm library diversity. 
 
 
Figure 3-11: Cyclic scFv cloned into yeast expression vector.  
The scFv libraries were cloned into the NruI restriction site of pIL500 in between the IC and IN 
domain of the Ssp-Npu split intein. The IC and IN domains of the Ssp-Npu split intein will 
catalyze a cyclization reaction to cyclize the scFv and second linker. This plasmid contains the 
same promoter, terminator, fusion cassette and markers as pIL500.  
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 3.4 ScFv Yeast Two-Hybrid Interaction Mating Assay 
 
3.4.1 Protein Domains used in Diploid Construction 
To ensure the binding capacity of the libraries was accurately sampled, a number of 
different protein domains were used. To avoid bias in favor of one library over another the 
protein domains used were diverse in composition and size. The breakpoint cluster region –
ableson kinase (BCR-ABL) protein domains (cc1-72, SH2, SH3, PxxP, FABD and Y177) used 
in this study were supplied by Alberto Aparicio, a graduate student in Dr. Geyer’s lab. Cc1-72 is 
the coiled coil domain from the BCR portion of BCR-ABL, amino acid residues 1- 72. The SH2 
and SH3 domains are from the ABL portion of BCR-ABL. The PxxP is a poly-proline region of 
BCR-ABL that is rich in proline residues. The FABD is a domain of BCR-ABL that binds f-
actin. Y177 is a phospho-tyrosine peptide from BCR-ABL.  
Hemopoietic cell kinase (Hck) tyrosine kinase domain was also used as a protein domain 
in this study. Hck was cloned out of pESC-Hck (A gift from Smithgall) and amplified by PCR in 
the following 100 µL reaction: 1 X PCR Buffer, 0.2 mM dNTPs, 0.2 µM P1 Hck 
TyrKin/pEG202 (#43 Table 3-1), 0.2 µM P2 Hck TyrKin/pEG202 (#44 Table 3-1), 1 µL pESC-
Hck plasmid, and 1 µL Taq polymerase. The PCR reaction was amplified in a thermocycler 
under the following conditions: 95 °C for 5 minutes, [95 °C for 30 seconds, 55 °C for 30 
seconds, 72 °C for 2 minute] (25 cycles), and 72 °C for 7 minutes. The amplified DNA from 
each protein domain was cloned into the yeast vector pEG202 (Figure 3-12) digested with EcoRI 
and XhoI the using lithium acetate transformation (76). 
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Figure 3-12: pEG202 yeast expression vector.   
pEG202 contains a constitutively active alcohol dehydrogenase (ADH) promoter, an alcohol 
dehyrdrogenase terminator (ADH Ter) and a 2 micron origin of replication (2 μ ori). The protein 
domains cloned into pEG202 were cloned into the EcoRI site and the XhoI site. When the protein 
domains are expressed they are tethered to a LexA binding domain (LexA) which will bind 
specifically to LexA binding sites on DNA within the yeast cell. pEG202 contains the third gene 
involved in histidine synthesis (HIS3) allowing cells containing this plasmid to grow on media 
lacking histidine. It also contains a gene for ampicillin resistance allowing cells containing this 
plasmid to grow in media containing ampicillin.  
 
 
 
3.4.2 Diploid construction 
Diploids were constructed using five out of the seven different protein domains (or baits) 
described above and one of the scFv libraries (Table 3-4).  
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Table 3-4: Baits Used in each Screen.  
*The number of scFv library members used in each screen is indicated in the top row. The 
protein domains from the Break point cluster region-Abelson kinase protein (BCR-ABL) and 
hemotopoietic cell kinase (HCK) are listed below. Protein domains used from BCR-ABL include 
src homology domain 2 (SH2), src homology domain 3 (SH3), residues 1-72 of the coiled coil 
oligomerization domain (cc1-72), tyrosine residue 177 + 10 flanking residues (Y177), F-actin 
binding domain (FABD), and the poly proline domain (PxxP). The src homology kinase domain 
was also used from HCK. 
 
The protein domains expressed in yeast strain EY111 were grown to an optical density of 
0.6-0.9 at 600 nm in SD H- media. The scFv library cells expressed in yeast strain EY93 were 
grown to an optical density of 0.6-0.9 at 600 nm in SD W- liquid media. Both cells were 
centrifuged at 3220 x g for 5 minutes at room temperature, washed in 1 mL of YPDA+ media 
and mixed at a 1:20 prey to bait ratio. The cells were gently mixed and incubated at room 
temperature for five minutes and spread onto YPDA+ media plates. The cells were grown 24 
hours at 30 °C, scraped off the plate, washed with 40 mL of ddH20 and resuspended in the pellet 
volume of glycerol freeze down solution and stored at – 80 °C. To count the diploids the cells 
were plated on SD H-W- plates and counted after two days of incubation at 30 °C. 
 
Number of Library 
members Screened 2.6 x 10
5
1 x 10
6
6 x 10
6
12 x 10
6
20 x 10
6
BCR-ABL SH2 BCR-ABL SH2 BCR-ABL SH2 BCR-ABL SH2 BCR-ABL SH2
BCR-ABL SH3 BCR-ABL SH3 BCR-ABL SH3 BCR-ABL cc1-72 BCR-ABL cc1-72
BCR-ABL cc1-72 BCR-ABL cc1-72 BCR-ABL cc1-72 BCR-ABL Y177 BCR-ABL Y177
BCR-ABL Y177 BCR-ABL Y177 BCR-ABL Y177 BCR-ABL PxxP BCR-ABL PxxP
HCK SH1 HCK SH1 HCK SH1 BCR-ABL FABD BCR-ABL FABD
K3 K3 K3 K3 K3
K4 K4 K4 K4 cK3
cK4 cK4 cK4 cK4 K4
T3 T3 T3 T3 cK4
T4 T4 T4 cT3 T3
cT4 cT4 cT4 T4 cT3
cT4 T4
cT4
Protein Domains Used
Libraries Screened
 45 
3.4.3 Yeast Two-Hybrid Interaction Assay 
Diploids were plated on to SG/R H-W-L- media plates and incubated at 30 °C for seven 
days. The plates were replica plated to SG/R H-W-A- -X-gal media plates with velvet and grown 
for up for five days at 30 °C. The number of colonies were counted and recorded.  
 
3.4.4 Quantitative Analysis for the Screening Results 
Each library was screened in quintuplicate to measure error and reproducibility. The set 
of data from each screen was averaged to get the number of positive hits from each screen. The 
number of positive hits from each screen was normalized to compare the cyclic and linear 
libraries by calculating the ratio of positive hits obtained from the cyclic library divided by the 
number of positive hits obtained from the linear library. The number of positive hits from each 
screen was normalized to compare the number of diversified CDRs by dividing the number of 
positive hits obtained by the three CDR libraries by positive hits obtained from the four CDR 
libraries. The number of positive hits from each screen was also normalized to compare the 
number of amino acids used to diversify the CDRs by dividing the positive hits obtained from 
the four amino acid libraries by the two amino acid libraries. The ratio of positive hits from each 
screen was plotted against the number of scFv library members screened to determine the trend 
of each parameter. The error bars reported reflect the standard deviation. The P values for each 
graph using a two-tailed analysis was determined by Graph Pad Prism version 4.0c for 
Macintosh. 
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3.5 Protein Expression of ScFv Constructs 
 
3.5.1 Expression of ScFv Proteins in Yeast  
A colony expressing a single scFv protein was grown up for 24 hours shaking in liquid 
SD W- media at 30 °C. The cells were collected at 3220 x g for five minutes at room temperature 
and washed in 1 mL of ddH2O. The cells were induced in 10 mL of SG/R W- at 30 °C for eight 
hours and collected by centrifugation at 3220 x g.  
 
3.5.1.1 Protein L purification of scFvs 
After induction of scFv proteins and collection of the cells, the pellets were resuspended 
in 300 µL of protein L binding buffer (20 mM Na2HPO4, 0.15 M NaCl, pH 7.0), 3 µL 1 mM 
PMSF (Sigma Aldrich Chemical Co., Canada), and 0.3 g acid-washed glass beads (425-600 μm) 
(Sigma Aldrich Chemical Co.). The cells were ruptured using Fast PrepFP120 (Thermo Savant, 
USA) for twenty seconds and setting 6.0 at 4 °C three times. The cell lysate was centrifuged 
twice at 4 °C at 18 000 x g for fifteen minutes and the supernatant was applied to protein L resin 
(Gene Script Corporation, USA). The cell lysate was incubated on the protein L resin overnight 
at 4 °C gently shaking. The protein L beads and lysate were applied to a microcron centrifugal 
filter column (Millipore, USA) and centrifuged at 1000 x g for 30 seconds at room temperature. 
The beads were washed three times with binding buffer and eluted in 0.1 M citric acid pH 3.0. At 
each step the samples were collected and added to 2x SDS-loading buffer (62.5 mM Tri-HCl, pH 
6.8, 0.25% (v/v) glycerol, 2% (w/v) SDS, 0.01% (w/v) bromophenol blue (Fischer Biotech, 
USA), 0.05% (v/v) β-mercaptoethanol), heated to 95 °C for 5 minutes and analyzed by Western 
blot 
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3.5.1.2 Western blotting 
Cells expressing scFv proteins that were not purified by protein L beads were extracted 
using a protocol previously described (79). The extracted proteins were loaded into a 4% 
stacking gel 15% resolving gel SDS-PAGE and separated for 15 minutes at 100 V and 35 
minutes at 200 V. The gel and nitrocellulose were incubated in transblot buffer, pH 8.3 (48 mM 
Tris, 39 mM glycine, 20% (v/v) methanol, 0.04% (w/v) SDS) for 10 minutes. The gel was 
electro-blotted with a transblot SD semi dry transfer (BioRad, Canada) to nitrocellulose 
(BioRad) at 15 V for 35 minutes. The blot was incubated in blocking buffer (Licor Biosciences, 
USA) for one hour and incubated with primary antibody cocktail (10 mL blocking buffer, 
0.0005% (v/v) Tween 20, 60 uL HA antibody (Santa Cruz Biotechnology, USA)) overnight. The 
next day the blot was washed with 1 X PBS-Tween, pH 7.4 (1.37 M NaCl, 26.8 mM KCl, 10 
mM Na2HPO4·7H2O, 17.6 mM KH2PO4, 0.001% (v/v) Tween 20) three times and incubated with 
secondary antibody cocktail (10 mL blocking buffer, 0.0005% (v/v) Tween 20, 2.5 uL anti-
mouse antibody (Licor Biosciences)) for one hour. The blot was analyzed on a Licor Odessey 
infrared imaging system (Licor Biosciences).  
 
3.5.2 Expression of ScFv Proteins in E. coli  
ScFv proteins were expressed in E. coli to obtain more protein to analyze the scFvs.  
 
3.5.2.1 Cloning scFvs into an inducible E. coli expression vector 
The scFv was cloned from the yeast expression vector (pIL500) and into a bacterial 
expression vector (pET28b). The scFv DNA was amplified in the following reaction: 1 X PCR 
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Buffer, 0.2 mM dNTPs, 1 μL of pIL500 expressing a scFv, 0.4 μM P1 Intein/EcoRI+1 (for cyclic 
scFvs or P1 pET28b/VH3-74 for linear scFvs) (#41 and #39 Table 3-1), 0.4 μM P2 Intein-
Npu/XhoI (for cyclic scFvs or P2 L19/pET28b for linear scFvs) (#42 and 40 Table 3-1), and 1 μL 
Taq polymerase. The PCR reaction was amplified in a thermocycler under the following 
conditions: 95 °C for 2 minutes, [95 °C for 30 seconds, 55 °C for 30 seconds, 72 °C for 2 
minute] (25 cycles), and 72 °C for 7 minutes. pET28b and the amplified scFv PCR were digested 
with 0.5 units of EcoRI and 0.5 units of XhoI in a 100 µL reaction. Digested pET28b and 
digested scFv PCR fragments were purified by gel electrophoresis to get rid of contaminating 
DNA using QIAquick gel extraction kit according to manufacturer’s instructions. The gel 
purified plasmid DNA (or vector DNA) and gel purified scFv PCR (or insert DNA) were mixed 
in a 1:3 molar ratio of insert DNA to vector DNA along with 1X ligation buffer (New England 
Biolabs) and 1 μL T4 DNA ligase (New England Biolabs) in a 20 μL reaction. The reaction was 
incubated at room temperature for 24 hours. Three microlitres of the ligation reaction was 
transformed by electroporation (80) into 50 μL of XL1Blue electrocompetent cells to obtain high 
quality plasmid DNA and optimal propagation of plasmid DNA. The transformed cells were 
grown in 500 μL of LB for one hour at 37 °C, plated on LB-Kanamycin plates and incubated at 
37 °C overnight. A colony was selected from the plate and grown up in LB-Kanamycin liquid 
medium at 37 °C overnight. The plasmid was isolated using QIAPrep Spin Miniprep Kit 
according to manufacturer’s instructions.  
The isolated plasmid was transformed by electroporation into BL21 codon plus 
electrocompetent cells to allow for protein induction. The transformed cells were grown up in 
LB-Kanamycin liquid medium at 37°C overnight. The cells were diluted to an optical density at 
600 nm of 0.2 and grown for approximately 2 hours until an optical density at 600 nm of 0.6-0.9 
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was reached. The cells were induced with 1 mM IPTG and grown at room temperature shaking 
for 24 hours. The cells were collected by centrifugation at room temperature at 3220 x g for 10 
minutes. 
The cells were resuspended in 600 µL of Buffer B pH 8.0 (100 mM NaH2PO4·H2O, 10 
mM Tri-Cl, 8 M urea), 0.3 g of acid-washed glass beads (425 – 600 μm) and 1 mM PMSF. The 
cells were ruptured using Fast PrepFP120 (Thermo Savant) for twenty seconds and 6.0 setting at 
4 °C three times. The cell lysate was centrifuged at 18 000 x g for 15 minutes two times at 4 °C. 
The supernatant was then applied to a histidine tag-Ni Column to purify the scFv. 
 
 
 
Figure 3-13: pET28b E. coli expression vector.  
pET28b contains a T7 promoter, a T7 terminator and a F1 origin of replication (F1 ori). The 
scFvs cloned into this vector were cloned in through the EcoRI and XhoI restriction sites. They 
are expressed tethered to a poly-histidine tag (His Tag). The histidine tag consists of six 
consecutive histidines that can be purified with a nickel column due to the histidine tag’s affinity 
for Nickel. It also contains a gene for kanamycin resistance allowing cells containing this 
plasmid to grow in media containing kanamycin.  
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3.5.2.2 Histidine tag-Ni column purification 
The scFv was purified using the histidine tag to test the difference in stability and 
solubility between the linear and cyclic versions of the scFv. The extracted protein lysate 
containing the histidine-tagged scFv was applied to His-Select Affinity Nickel Gel (Sigma 
Aldrich Chemical Co.) for 30 minutes at room temperature with slow, gentle back and forth 
rocking. The gel and lysate were centrifuged at 1000 x g at room temperature for 30 seconds, the 
flow through lysate was collected. The beads were washed three times with Buffer B and eluted 
in Buffer B containing 500 mM imidazole (protein elution ‘A’). At each step the samples were 
collected and separated on a 4% stacking gel 15% resolving SDS-PAGE. Protein elution ‘A’ was 
eluted through a protein L column subsequently to examine the scFv folding correctness. 
 
3.5.2.3 Renaturation of the scFv protein 
To test the correct folding of the scFvs protein elution ‘A’ was applied to a protein L 
column, which will bind scFvs if they are correctly folded. To bind to protein L the scFvs must 
be in their native form. The scFvs were successfully purified only under denaturing conditions so 
to test the correct folding they were renatured. The extracted protein lysate containing the 
histidine-tagged scFv were applied to His-Select Affinity Nickel for 30 minutes at room 
temperature with slow, gentle back and forth rocking. The beads and lysate was centrifuged at 
1000 x g at room temperature for 30 seconds, the flow through lysate was collected. The beads 
were washed with decreasing concentrations at a 2 M gradient of urea for 30 minutes at each 
concentration and without urea three times. The scFvs were eluted in Buffer B containing 500 
mM imidazole.  At each step the samples were collected and separated on a 4% stacking gel 15% 
resolving SDS-PAGE. 
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3.5.2.4 Protein L purification of scFvs 
After renaturing the scFv, the elution was applied to protein L resin and incubated 
overnight at 4 ºC with slow, gentle back and forth rocking. The next day the flow through was 
collected. The beads were washed three times with Buffer B and eluted in 0.1 M citric acid, pH 
3.0. At each step the samples were collected and separated in a 4% stacking gel 15% resolving 
SDS-PAGE. 
 
3.5.2.5 SDS-PAGE 
Reduced and non-reduced samples of the cell lysates, washes and elutions from the beads 
were analyzed by SDS-PAGE. The samples were mixed with 1x SDS loading buffer, heated at 
95 ºC for 5 minutes and loaded a 4% stacking gel 15% resolving SDS-PAGE and separated for 
15 minutes at 100 V and 35 minutes at 200 V. The gel was incubated in fixing solution (25% 
(v/v) isopropanol, 10% (v/v) acetic acid) for fifteen minutes and stained in Coomasie blue stain 
(10% (v/v) acetic acid, 0.012% (w/v) bromophenol blue) for 4 hours. The gel was incubated in 
destain solution (10% (v/v) acetic acid) until the bands became clearly visible. The gel was 
analyzed on a Licor Odessey infrared imaging. 
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Chapter 4 Results 
 
4.1 Construction of Libraries 
Single chain variable fragments (scFvs) have six complementarity determining regions 
(CDRs), three on the heavy chain and three on the light chain (Figure 4-1). These CDRs are 
responsible for the highly specific interactions between the antibody and the antigen. The goal of 
this project is to create synthetic scFv libraries that are capable of binding a variety of antigens 
with high affinity and specificity. To do this, scFv libraries were constructed that varied in (i) 
amino acid diversity within the CDRs; (ii) the number of CDRs varied; and (iii) configuration 
(cyclic versus linear). The scFv libraries were produced in S. cerevisiae. This model organism 
provides a eukaryotic cell environment similar to that of humans, which is the projected 
destination for scFv expression. The reducing environment inside the cell does not support the 
disulphide bonds that stabilize the scFv structure and therefore the scFvs are not stably 
expressed. By expressing scFvs in S. cerevisiae the yeast two-hybrid assay can be used to isolate 
scFvs. By using this assay the scFvs isolated should be properly folded and expressed within the 
yeast cell.   
The scFvs produced in this study were based on scFvs previously reported. The scFv 
framework used in this study was modeled after the consensus framework found by Tse et al. 
who established an scFv framework consensus sequence that is highly expressed in yeast (74). 
Tanaka et al. showed that this framework can be used with other CDRs (73). The CDR residues 
varied within the framework were modeled after observations by Fellouse et al; who determined 
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important CDR residues involved in binding by solving crystal structures of antigen-antibody 
fragment complexes (8).  
There are approximately 20 variable positions within the CDRs that come into contact 
with the antigen (30). A library containing scFvs with all the possible combinations of 20 amino 
acids in 20 different positions; 2020 ~ 1.0 x 1026 far exceed the number of cells that can be 
produced and screened in yeast. By reducing the number of amino acids used and the variable 
number of CDRs, a simpler library can be produced. The goal was to maximize binding of scFvs 
to a variety of antigens while minimizing the size of the scFv library. To do this, scFv libraries 
were created based on previous results. Four or two amino acids were used to diversify the CDRs 
instead of the twenty found in the natural repertoire. Three or four CDRs were diversified instead 
of six. 
Eight scFv libraries were constructed that differed in the number of variable amino acids, 
the number of CDRs varied and scFv configuration. The scFv libraries are listed in Figure 4-1. 
The scFv configuration within the libraries was either cyclic or linear (c or L). The letters K and 
T were used to represent the number of amino acids encoded by the degenerate codon, KMT or 
TMT. KMT encodes four different amino acids (tyrosine, serine, alanine and aspartate) and TMT 
encodes two different amino acids (tyrosine and serine). Therefore, in the library nomenclature T 
= two amino acids and K = four amino acids. There were three or four variable CDRs within 
each scFv library, which is represented as the number at the end of the library name. Initially, six 
scFv libraries (LT3, LK3, LT4, cT4, LK4, cK4) were created. These libraries were screened 
using the yeast two-hybrid assay to determine the effect of the variable parameters on the library 
binding capacity. The cyclic three variable CDR libraries were not initially created as it was 
assumed that the four variable libraries would have a larger binding capacity. The six libraries 
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were screened in three separate assays. These three screens revealed that the cyclic scFv libraries 
had a larger binding capacity than the linear scFv libraries. To confirm that this trend also held 
for the three variable CDR libraries, two additional cyclic libraries (cT3, cK3) were created.  
 
 
 
Figure 4-1: ScFv libraries created.  
The scFv structure is shown in the left panel. The scFv is made of the variable heavy chain 
domain (VH) and the variable light chain domain (VL) of a natural antibody. There are three 
complementarity determining regions (CDRs) located on each the VH and VL. In the right panel 
the names of the different libraries are given in the first column. The first letter indicates linear 
(L) or cyclic (c), the second letter indicates number of amino acids K (four) or T (two) and the 
number indicates the number of CDRs.  
 
 
The first parameter tested was the number of amino acids used to vary the CDRs. This 
parameter affects the library size immensely. For example using two or four amino acids 
dramatically decreases the size of the library compared to using all 20; a two amino acid library 
varied at twenty positions contains 220 members, a four amino acid library varied at twenty 
positions contains 420 members and a twenty amino acid library varied at twenty positions 
contains 2020members. Studies have shown that the number of amino acids can be reduced to two 
amino acids (tyrosine and serine) and high affinity Fabs can still be isolated (81). In this study, 
the CDRs were varied using either two amino acids (tyrosine and serine) or four amino acids 
(tyrosine, serine, alanine and aspartate). Fellouse et al previously showed that this minimal 
H2
H3
H1 L1
L3
L2
Library Name Configuration Amino Acids CDRs Varied
LT3 Linear Tyrosine, Serine H1, H2, H3
cT3 Cyclic Tyrosine, Serine H1, H2, H3
LT4 Linear Tyrosine, Serine H1, H2, H3, L3
cT4 Cyclic Tyrosine, Serine H1, H2, H3, L3
LK3 Linear Tyrosine, Serine, Alanine, Aspartate H1, H2, H3
cK3 Cyclic Tyrosine, Serine, Alanine, Aspartate H1, H2, H3
LK4 Linear Tyrosine, Serine, Alanine, Aspartate H1, H2, H3, L3
cK4 Cyclic Tyrosine, Serine, Alanine, Aspartate H1, H2, H3, L3
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diversity is enough to create highly specific Fab binders to a variety of antigens (8,9). The 
number of variable CDRs also affects the library size.  
Each CDR contains a different number of amino acids that contribute to antigen binding. 
Based on previous results, CDR L1 and CDR L2 were not varied in this study. In four of the 
scFv libraries, only the three heavy chain CDRs were varied and in the other four the heavy 
chain CDRs as well as CDR L3 was varied (Figure 4-1). The residues within the CDRs were 
varied based on the scFv used by Fellouse et al (Figure 3-5) (8). By decreasing both the number 
of CDRs varied and the amino acids varied within them, the diversity of the library was greatly 
reduced. 
The configuration does not affect library diversity or size; it is proposed to affect the 
stability of the library and, therefore is proposed to increase library functionality by increasing 
the number of properly folded scFvs. The functional diversity is described as the approximate 
number of the scFvs within an scFv library that contains the correct sequence information. The 
functional diversity was determined as a percentage of scFvs with the correct sequence out of a 
sample of 50 scFvs that were sequenced from each library. The scFv structure is inherently 
unstable since it is only stabilized by hydrophobic interactions between the two variable 
domains. The intra-domain disulphide bonds, which normally assist in stability, do not form 
within the cell (Figure 4-1) (37). Thus intracellular scFvs can unfold leading to aggregation and 
decreased solubility, which hinders binding (41). By cyclizing the scFv it should prevent 
aggregation and increased stability (12,13). This should increase the number of properly folded 
scFvs within the library and the ability of the scFvs to interact with their target; thus, increasing 
the binding capacity of the cyclic libraries versus the linear libraries.  
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The libraries were constructed using yeast homologous gap repair mechanism in a series 
of steps. The scFv library framework with restriction sites in place of the heavy chain CDRs was 
constructed from eighteen overlapping oligonucleotides by PCR amplification. CDR H3 was 
PCR amplified and cloned into the scFv framework. This plasmid was amplified and CDR H1 
and H2 were cloned into the scFv framework containing CDR H3. This gave rise to the linear 
scFv libraries containing three variable CDRs (K3, T3).  The four variable CDR scFv libraries 
were made from the three variable CDR scFv libraries. The three variable CDR scFv libraries 
were PCR amplified using mutagenic primers that diversify CDR L3. The primers contained 
degenerate codons to add diversity to CDR L3. The PCR amplified scFv libraries were cloned 
into the plasmid (pIL500) generating the linear four variable CDR libraries (K4, T4). The cyclic 
libraries were created from the linear libraries. To create the linear libraries were PCR amplified 
and cloned into a vector containing the intein machinery necessary for protein cyclization. This 
created a slight artificial bias against the libraries containing four variable CDRs and the cyclic 
libraries that were PCR amplified from the libraries with three variable CDRs and linear 
libraries, which potentially reduces their diversity. 
 
4.1.1 Diversity of libraries 
The theoretical diversity of each library is indicated in Table 4-1 and is calculated by 
taking the number of varied amino acids raised to the power of the total number of variable 
residues within the CDRs. The obtained diversity of the scFv libraries is determined by the 
efficiency of the yeast transformation. The scFv libraries were created using three different 
cloning steps. The transformation efficiency at the last step was recorded as the library diversity. 
It is assumed every successful transformant is a unique scFv library member containing a 
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different CDR sequence. Fifty library members were sequenced from each library to analyze the 
library diversities. All scFvs analyzed had different CDR sequences. From the fifty sequences 
obtained from each of the libraries, a percent of functional library members was calculated. The 
functional percentage was multiplied by the obtained diversity to obtain the functional diversity. 
The functional diversity represents the number of scFvs within the library with the correct 
sequence.  
Table 4-1: ScFv library diversities.  
*The name of the library is indicated in the first column where L = linear, c = cyclic, K = four 
amino acids, T = two amino acids, 3 = 3 CDRs, and 4 = 4 CDRs. The variable number of amino 
acid residues within complementarity determining regions (CDRs) and the number of amino 
acids varied in those positions are indicated in the second and third columns. The theoretical 
diversity is the total number of possible unique members. The theoretical diversity was 
calculated using the number of amino acids varied raised to the power of the number of varied 
CDRs. (ie LK3, 23 different positions, 4 amino acids; 423= 7 x 1013). The obtained diversity is the 
number of transformants obtained after the final transformation. The functional diversity is an 
approximate percent of scFvs with the correct scFv sequence taken from a sample of fifty 
members from each library. The functional diversity is the product of the obtained diversity and 
the functional percent to give the approximate number of unique and functional scFvs from each 
library. 
  
 
The functional percentage is used to normalize the number of functional scFvs mated and 
screened. For example, in the LK3 library, if 1 x 106 cells from each library are screened, the 
Library
Variable 
CDRs
Vaiable amino 
acids
Theoretical 
Diversity
Obtained 
Diversity
Functional 
(%)
Functional 
Diversity
LK3 18 4 6.9 x 10
10
5.4 x 10
7
73 3.9 x 10
7
cK3 18 4 6.9 x 10
10
2.0 x 10
7
60 1.2 x 10
7
LK4 23 4 7.0 x 10
13
2.0 x 10
7
52 1.0 x 10
7
cK4 23 4 7.0 x 10
13
2.2 x 10
6
41 9.0 x 10
5
LT3 18 2 2.6 x 10
5
8.0 x 10
5
67 5.4 x 10
5
cT3 18 2 2.6 x 10
5
7.0 x 10
5
60 4.2 x 10
5
LT4 23 2 8.4 x 10
6
4.2 x 10
6
51 2.1 x 10
6
cT4 23 2 8.4 x 10
6
4.2 x 10
6
65 2.7 x 10
6
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number of LK3 cells that need to be plated in order to have 1 x 106 functional scFvs is [(1 x 106 x 
0.27) + 1 x 106] = 1.27 x 106. All the library screens are adjusted in this manner.  
 
4.1.2 Cyclization of scFv libraries 
ScFvs are inherently unstable inside cells. ScFvs contain disulphide bonds that stabilize 
their structure but they are not formed inside of cells. The limited intracellular stability of scFvs 
is due to the hydrophobic bonds between the two variable domains (37). Without the extra 
stability from the intra-domain disulphide bonds, scFvs have a tendency to unfold and aggregate. 
When aggregated, scFvs precipitate out of solution and are not functional. Studies have shown 
that cyclization of proteins can increase stability, solubility, and/or folding ability while still 
retaining activity (12,13). The intein is a self-splicing protein whose potential has been harnessed 
to successfully cyclize proteins in vivo (Figure 2-5) (54).  
In attempt to stabilize the scFv structure, linear scFv libraries were cloned into a vector 
containing the intein machinery that has been used to successfully cyclize proteins in previous 
reports (58) and in our lab. ESI-TOF mass spectroscopy was used to analyze the cyclization of 
single scFvs. The analysis of the scFvs by mass spectrometery was not successful, which could 
be due to the size of the scFv or the scFv not being appropriately charged. To see if the cyclic 
and linear scFv were being expressed and the intein was processing, they were separated by 
SDS-PAGE (Figure 4-2). The two scFvs were identical in their CDR sequences and only differed 
in configuration. They were denatured, purified using nickel beads and separated by SDS-PAGE. 
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Figure 4-2: SDS-PAGE analysis of scFvs expressed in E. coli.   
A cyclic and linear scFv, containing the same CDRs were induced for 24 hours and bound to 
nickel beads. The beads were washed, eluted and separated in a 4% stacking 15% resolving 
SDS-PAGE and stained with coomassie blue stain. (a) Cyclic scFv; lane M, standard pre-stained 
protein marker; lane 1, uninduced; lane 2, induced; lane 3, crude cell lysate before incubation 
with nickel beads; lane 4, flow through lysate that did not bind the nickel beads; lane 5, wash 1; 
lane 6, wash 2; lane 7, elution from the nickel beads. (b) Linear scFv; lane M, standard pre-
stained protein marker; lane 1, induced; lane 2, uninduced; lane 3, crude cell lysate before 
incubation with nickel beads; lane 4, flow through lysate that did not bind the nickel beads; lane 
5, wash 1; lane 6, wash 2; lane 7, wash 3; lane 8, elution from the nickel beads. The arrows 
indicate the major protein products purified by the nickel beads. In (a) the top bands is the 
unprocessed, the middle band may be a degraded version of the unprocessed and the lower band 
is the cyclized version of the scFv. In (b) the arrow indicates the linear version of the scFv. 
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The linear and cyclic scFvs are approximately 31 kDa and 36 kDa, respectively. There 
were three major bands in the cyclic scFv elution, one that ran around 35 kDa and the other two 
ran in between the 35 and 55 kDa markers (Figure 4-2). The cyclic scFv is 36 kDa, which 
corresponds with the lower band. The unprocessed scFv (scFv + N-intein + C-intein) is 
approximately 48 kDa. Depending on cyclization efficiency there will usually be some 
unprocessed scFv present. The largest band in the cyclic gel corresponds to the unprocessed scFv 
and the other band is likely the folded unprocessed or a splicing intermediate of the unprocessed 
intein. The third band in the elution corresponds to the cyclic scFv. There is one major band in 
the linear gel that ran at approximately 31 kDa, which corresponds with the linear scFv. Since 
the unprocessed and processed versions of the scFv are visible, it indicates that the intein is 
processing the scFv, which is a good indication that the scFv is being cyclized. 
 
4.2 Library Screening 
To evaluate the scFv libraries for binding capacity, several protein domains were chosen 
to screen as targets against each of the libraries using the yeast two-hybrid assay (Figure 2-6). 
Five different screens were done with different protein domains and the libraries at different 
mating densities (Table 3-4). To screen the libraries, yeast cells expressing the protein domains 
and yeast cells expressing the library were separately grown to OD600 = 0.6-0.9. The bait cells 
were pooled and mated separately with each library. The mated cells were screened first on weak 
selection media (SG/R H-W-L-) and later replica plated to a stronger selection media (SG/R H-W-
A- -X-gal). This two-step screening procedure has been shown previously to reduce false positive 
results in the yeast two-hybrid assay (83). 
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4.2.1 Protein domains used in the interaction mating assay  
The protein domains used in the interaction mating assay portion of this study are 
domains from BCR-ABL and HCK (Table 3-4). Both BCR-ABL and HCK contribute to chronic 
myelogenous leukemia (CML). BCR-ABL is an oncogene fusion product that is found in CML 
signaling pathways (84). BCR-ABL is created by a reciprocal translocation between 
chromosomes 9 and 22 to produce the novel fusion protein BCR-ABL (84). HCK is one of the 
proteins that BCR-ABL activates and sends signals through. HCK is activated by BCR-ABL, 
which in turn phosphorylates BCR-ABL and other targets spreading the transforming signal (85). 
HCK and BCR-ABL have been shown to interact through the SH3 domain of HCK and SH1, 
SH2, and SH3 domains of BCR-ABL, as well as the C-terminal domain of ABL which contains 
the F-actin binding domain (86). BCR-ABL and HCK were used as targets in the yeast two-
hybrid assay to evaluate the scFv libraries. 
Five out of the seven domains were used in each screen. The domains used from BCR-
ABL included: the coiled coil domain (cc1-72), src homology 2 (SH2), src homology 3 (SH3), 
poly-proline (PxxP), tyrosine residue 177 flanked by ten amino acid residues (Y177), and f-actin 
binding domain (FABD). The SH1 tyrosine kinase domain from HCK was also used. HCK and 
BCR-ABL were split into domains because they are very large proteins and targeting an single 
protein domain leads to a more specific protein interaction, which will allow the user to better 
predict the function of the targeting protein in a cell. For example, since BCR-ABL and HCK 
interact through BCR-ABL SH1, SH2 and SH3, obtaining an scFv specific for one of these 
domains should have an effect on this interaction, whereas blindly targeting the whole protein 
does not ensure that an important interaction will be disrupted. The domains used in this study 
are structurally diverse to prevent any bias among the binding capabilities of the different 
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libraries. The cc1-72 domain is made up of two or three α-helices (87). The SH2 is made up of 
three-stranded anti-parallel β-sheets and two flanking α-helices (88,89). The SH3 domain 
consists of five β-strands that form a β-sandwich with two tightly packed anti-parallel β-sheets 
with one long β-hair-pin turn (89). Y177 is a tyrosine that is involved in downstream signaling 
(90,91). The Y177 domain comprises of eleven amino acids in total with tyrosine 177 in the 
middle. The PxxP is a poly-proline rich region (92). The FABD is made up a 4 α-helical bundle 
(93). These different protein domains were used as baits to screen the scFv libraries.  
 
4.2.2 Screen Results 
The output of the yeast two-hybrid assay measures the ‘binding capacity’ or number of 
interactions per number of diploids screened. It is difficult to test the binding capacity of the 
libraries because of the large range in diversity between the libraries.  To address this issue, the 
libraries were screened five times, each with a different amount of library members (Table 3-4). 
Initially, six scFv libraries (T3, T4, cT4, K3, K4, cK4) were made to test the differences imposed 
by the different parameters (Figure 4-1). Since the smallest library contained 2.6 x 105 members, 
the first screen was done with 2.6 x 105 library members.  
The six libraries were screened two more times with one million and six million library 
members to compare the results obtained in the first screen (Table 3-4). There was no clear trend 
with respect to number of amino acids or number of variable CDRs; however, the first three 
screens showed in all cases that the cyclic scFv libraries contained a larger binding capacity than 
the linear.  
The cT3 and cK3 libraries were made after these compelling results regarding scFv 
cyclization. In the fourth screen twelve million library members from each library were screened 
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which included the cT3 library. The cyclic scFv libraries again contained a higher binding 
capacity compared to the linear libraries. The cK3 library was produced and screened along with 
the seven other libraries using twenty million scFv library members in the fifth screen. The trend 
observed among the first four screens persisted, showing that the cyclized libraries had a larger 
binding capacity than the linear libraries. This reoccurring trend was of particular interest as it 
alluded to the fact that cyclization was stabilizing the scFv structure enabling them to bind more 
targets. 
 
4.2.3 Cyclic versus linear in binding capacity 
When expressed inside a cell, the linear scFv structure is only stabilized by hydrophobic 
interactions between the two domains and the linker peptide, which tethers the two domains 
together (5). For this reason scFvs are unstable, prone to unfolding, and form aggregates, which 
makes most scFvs insoluble (39,40). When proteins form aggregates, they are unable to function 
because they precipitate out of solution (39,40).  
In this study, four cyclic scFv libraries and their linear counterparts were created to 
determine what effect cyclizing has on their binding capacity. The cyclic scFv libraries had a 
higher binding capacity than the linear libraries in all five screens (Figure 4-3). To compare the 
different screens, each screen was normalized by taking the ratio of the cyclic library over the 
linear library. In all five screens, the cyclic scFv libraries have a statistically significant 
difference (P values < 0.05) in binding capacity when compared to the linear scFv library 
counterpart. Not only was the difference between the cyclic and linear library in each screen 
significant the cyclic libraries always had a higher binding capacity than the linear libraries. 
 64 
 
Figure 4-3: Ratios comparing cyclic configuration to linear.  
The screens are listed along the x-axis; screen 1 = 2.6 x 105 library members, 2 = 1 x 106 library 
members, 3 = 6 x 106 library members, 4 = 12 x 106 library members, and 5 = 20 x 106 library 
members. The ratio of positive interactions per diploid from each screen is represented on the y-
axis as the cyclic interactions divided by the linear interactions. The error bars represent the 
standard deviation from five plates used for each screen. The average of the ratios is indicated in 
the lane six. The asterisk (*) indicates statistical significance (P value < 0.05) between the cyclic 
and linear scFv library binding capacities. Data is not available (N/A) for some of the screens 
with cT3 and cK3, which were not yet produced at the time of the screen. (a) The cyclic four 
amino acid four CDR library (cK4) compared to the linear four amino acid four CDR library 
(LK4). (b) The cyclic two amino acid four CDR library (cT4) compared to the linear two amino 
acid four CDR library (LT4). (c) The cyclic four amino acid three CDR library (cK3) compared 
to the linear four amino acid three CDR library (LK3). (d) The cyclic two amino acid three CDR 
library (cT3) compared to the linear two amino acid three CDR library (LT3). 
 
 
Cyclizing scFv libraries increased their binding capacity. This result is novel for scFvs 
and very useful for the generation of future scFv libraries. The increased binding capacity of the 
cyclic libraries can be attributed to the stabilization of the scFv structure.  
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The results found from these screens in regard to cyclic and linear are comparable 
because the sizes of the libraries being compared (cyclic vs. linear) are similar in size. When 
looking at functional diversities the linear T libraries are similar sizes to their cyclic counterpart 
(Table 4-1). The K libraries diversities are very different when comparing the corresponding 
cyclic and linear libraries. The cK4 library is less than one tenth of the size of the LK4 and the 
cK3 library is approximately one quarter the size of the LK3. This is interesting because despite 
the lower functional diversity of the cyclic libraries they still had larger binding capacities. This 
is strong evidence that cyclizing the scFv structure increases its folding capability and its 
stability, thus increasing its binding capacity. Whether cyclizing the scFv increases its stability 
and solubility compared to the linear version will have to be measured to confirm these results.  
 
4.2.4 Binding capacity of three and four variable CDRs  
To determine if more CDR diversity results in a larger binding three or four out of six 
CDRs were varied. Important CDRs within the antibody-antigen complex vary depending on the 
complex being analyzed. The heavy chain interacts with its target more than the light chain (31). 
Each CDR contains a different number of amino acids that contribute to antigen binding. For 
example, CDR H3 has been shown to be the most important in antigen interactions (30,31,32). 
CDR H3 is found in the middle of the binding pocket and is the most variable CDR in terms of 
size, conformation, and composition (32). CDR H2 and CDR H1 contribute more than the light 
chain but less than CDR H3 in binding to the antigen (30,31,32). Interactions between the light 
chain and antigen are also dependent on the complex being analyzed. CDR L3 contacts the 
antigen the most CDR L1 and CDR L2 contributes less or sometimes not at all (82). 
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Using these previous results as a guide, CDRs H1, H2, and H3 of the heavy chain were 
varied in four libraries and CDRs H1, H2, H3 from the heavy chain and L3 from the light chain 
were varied in four libraries (Figure 3-5). It was hypothesized that the four variable CDR 
libraries would have a higher binding capacity than the three variable CDR libraries because they 
are more diverse. The trend when comparing the binding capacity of the scFv libraries with three 
CDRs and the scFv libraries with four did not follow this logic. In 11 out of 13 screens, the three 
CDR libraries had a higher binding capacity than the four CDR libraries (Figure 4-4). Seven out 
of ten had a statistically significant difference (P value < 0.05). The two amino acid three CDR 
libraries had a larger binding capacity than the two amino acid four CDR libraries. It is difficult 
to comment on the two amino acid cyclic libraries when only two screens were done, however, 
four out of five screens with the two amino acid linear libraries showed that three CDRs were 
better than four, three of these were statistically significant (P value < 0.05).  
The problem with fully accepting that three CDRs are better than four for the two amino 
acid libraries is the two cases where the four CDRs were statistically better (P value < 0.05). 
With the exception of these two cases these results concluded that the three CDR libraries had a 
larger binding capacity than the four CDR libraries.  
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Figure 4-4: Ratios comparing three CDRs to four CDRs.  
The screens are listed along the x-axis; screen 1 = 2.6 x 105 library members, 2 = 1 x 106 library 
members, 3 = 6 x 106 library members, 4 = 12 x 106 library members, and 5 = 20 x 106 library 
members. The ratio of positive interactions per diploid from each screen is represented on the y-
axis as the number of interactions from the three CDR libraries divided the number of 
interactions from the four CDR libraries. The error bars represent the standard deviation. The 
asterisk (*) indicates statistical significance (P value < 0.05). The average of the ratios is 
indicated in the lane six. Data is not available (N/A) for some of the screens with cT3 and cK3, 
which were not produced at the time of the screen. (a) The linear four amino acid three CDR 
library (LK3) compared to the linear four amino acid four CDR library (LK4). (b) The linear two 
amino acid three CDR library (LT3) compared to the linear two amino acid four CDR library 
(LT4). (c) The cyclic four amino acid three CDR library (cK3) compared to the cyclic four 
amino acid four CDR library (cK4). (d) The cyclic two amino acid three CDR library (cT3) 
compared to the cyclic two amino acid four CDR library (LT4). 
 
 
 
The scFv libraries with three diversified CDRs had a larger binding capacity than the 
libraries with four. This result could be attributed to there being less functional scFvs when the 
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ability of the scFvs to fold properly and therefore decrease the number of functional scFvs in the 
library (compared to the scFv libraries with three diversified CDRs). Diversifying the fourth 
CDR negatively affected the scFv folding so much that the binding capacity was not 
compensated by the increased diversity from the fourth CDR of the scFvs that do fold properly. 
 
4.2.5 Two variable amino acids versus four in CDR variability  
Minimal libraries produced with only four amino acids diversifying the CDRs are able to 
generate high affinity antibody fragments specific for all targeted antigens (8). The largest 
number of scFvs was isolated from the library with CDRs diversified with tyrosine, serine, 
alanine, and aspartate (8). Structural analysis revealed that tyrosine side chains are responsible 
for mediating most antigen recognition in Fab binding pockets and small amino acids like serine 
and alanine allowed for space and conformational flexibility for larger amino acids like tyrosine 
(8). To test this, smaller libraries with only tyrosine and serine randomizing the CDRs were 
created (9). The serine-tyrosine library was able to isolate specific interactions against a broad 
range of targets.   
The libraries created for this study were modeled from previous results with the goal of 
producing scFv libraries with decreased diversity without sacrificing binding capacity. Eight 
scFv libraries were created. To decrease the diversity the scFv CDRs were varied with two or 
four amino acids. The CDRs were varied with serine and tyrosine or serine, tyrosine, alanine, 
and aspartate. The hypothesis was that the four amino acid libraries would have a higher binding 
capacity.  
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Figure 4-5: Ratios comparing two amino acids to four amino acids.  
The screens are listed along the x-axis; screen 1 = 2.6 x 105 library members, 2 = 1 x 106 library 
members, 3 = 6 x 106 library members, 4 = 12 x 106 library members, and 5 = 20 x 106 library 
members. The ratio of positive interactions per diploid from each screen is represented on the y-
axis as the interactions from the four amino acid libraries divided by the interactions from the 
two amino acid libraries. The error bars are represented by the standard deviation. The asterisk 
(*) indicates a statistical significance (P value < 0.05). The average of the ratios is indicated in 
the lane six. Data is not available (N/A) for some of the screens with cT3 and cK3, which were 
not yet created at the time of the screen. (a) The linear four amino acid three CDR library (LK3) 
compared to the linear two amino acid three CDR library (LT3). (b) The linear four amino acid 
four CDR library (LK4) compared to the linear two amino acid four CDR library (LT4). (c) The 
cyclic four amino acid three CDR library (cK3) compared to the cyclic two amino acid three 
CDR library (cT3). (d) The cyclic four amino acid four CDR library (cK4) compared to the 
cyclic two amino acid four CDR library (cT4). 
 
 
 
The results regarding the two and four amino acid libraries showed that the libraries with 
three diversified CDRs, four amino acids libraries had a larger binding capacity than the two 
amino acid libraries (Figure 4-5). There was statistically significant differences (P value < 0.05) 
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supporting this observation in three out of six screens that show this trend. In the libraries with 
four diversified CDRs there was no difference in the binding capacity when comparing two and 
four amino acids. Statistically significant differences between the four CDR libraries comparing 
two and four amino acids were random. This is expected if neither two nor four amino acid 
libraries are better. When correlating these results with the other results in this study it showed 
that the three CDR libraries have improved binding capacity when the diversity is increased from 
two to four amino acids. This same trend was not observed when the fourth CDR, CDR L3 was 
diversified. There was no trend in the four CDR libraries when comparing two and four amino 
acids. This extra diversity can be attributed to the possible decrease in functional diversity (or 
folding of the scFvs), which is not compensated by the extra diversity from the fourth CDR. 
 
4.3 Expression of scFv constructs 
The scFvs were expressed in E. coli and S. cerevisiae to address if they are cyclizing and 
if they are more stable due to cyclization.  
 
4.3.1 ScFv expression in S. cerevisiae 
ScFvs isolated using the yeast two-hybrid assay were expressed in S. cerevisiae. It was 
hypothesized that the S. cerevisiae expression system would be the more likely system to 
produce correctly folded, active, and stable scFvs than E. coli because they were isolated from S. 
cerevisiae. Complex foreign eukaryotic protein expression is generally more successful in yeast 
compared to E. coli. ScFvs are difficult to express in bacteria due insolubility and formation of 
inclusion bodies (94). E. coli cells are limited in foreign protein expression because most 
proteins must be denatured before purification (95). 
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4.3.1.1 ScFv expression time course in S. cerevisiae 
ScFvs isolated from the yeast two-hybrid screens were used to analyze expression in 
yeast. The scFvs are expressed in S. cerevisiae from a galactose inducible promoter. The scFv is 
expressed tethered to a hemagglutin (HA) tag and an activation domain (Figure 4-7). The cyclic 
scFv is also expressed with the C-intein and the N-intein on the N-terminal and C-terminal ends 
of the scFv respectively. Cells expressing scFvs were induced with galactose for 24 hours. A 
time course of the expression of a cyclic scFv was monitored to determine the optimal induction 
time (Figure 4-6). Each time point was separated by SDS-PAGE and probed with α-HA 
antibody, to visualize the proteins containing the HA tag. 
 
 
 
 
Figure 4-6: Cyclic scFv expressed in S. cerevisiae.  
The scFv was induced for 24 hours and time points were taken. The cells were treated with 
NaOH rapid protein purification from yeast protocol as previously described (79). Fifteen μL of 
each sample was separated in a 4% stacking 15% resolving SDS-PAGE and Western blotted 
with α-HA antibody. Lane M, a pre-stained protein marker; lane 1, one hour of induction; lane 2, 
three hours of induction; lane 3, four hours of induction; lane 4, five hours of induction; lane 5, 
six hours of induction; lane 6, eight hours of induction; lane 7, nine and a half hours of induction; 
lane 8, 25 hours of induction. The arrow indicates where the cyclic scFv is. 
 
 
The cyclic scFv is approximately 42 kDa. There is a band that corresponds to this size 
shown in Figure 4-6. The expression of the cyclic scFv was optimized at 8 hours. The 
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unprocessed scFv was visible at approximately 55 kDa; its expression was most intense at eight 
hours. There was unprocessed and cyclic scFvs present, which indicated that the intein 
machinery is processing to produce cyclic scFvs. 
 
 
Figure 4-7: ScFv constructs expressed in S. cerevisiae.  
The unprocessed version of the scFv-intein will be visible where the intein mediated scFv 
cyclization reaction has not occurred. The unprocessed version is composed of the activation 
domain (AD) which is part of the yeast two-hybrid machinery that activates transcription, the C-
intein (IC) and N-intein (IN) catalyze the intein-mediated cyclization process, Hemagglutin tag 
(HA) for purifying and identifying the protein, and the scFv the protein of interest. The 
unprocessed scFv is approximately 55 kDa. The cyclic version of the scFv differs from 
unprocessed in that it has undergone the cyclization reaction cleaving off the N-intein domain 
ultimately cyclizing the scFv making the cyclic scFv approximately 42 kDa. The linear version 
of the scFv does not contain any of the of the intein machinery and is approximately 39 kDa. 
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4.3.1.2 ScFv protein L purification  
Protein L is a protein isolated from Peptostreptococcus magnus that has a natural ability 
to bind to antibody kappa light chain variable regions in their native conformation (52). Protein L 
can be used to purify antibodies and antibody fragments, such as scFvs from solution. ScFvs 
isolated from the yeast two-hybrid screen were induced for eight hours with galactose. The cells 
were ruptured and applied to protein L beads. The resin was washed, eluted and the samples 
were analyzed using a Western blot (data not shown). The scFv did not bind to the protein L 
column. A few different conditions were used, changes in buffers, incubation times and 
temperatures were made but still no binding was observed.  
 
4.3.2 ScFv expression in E. coli 
Expression of the scFvs in S. cerevisiae was expected to be more successful, however 
purifying the scFvs using protein L from was not successful. To obtain scFvs they were 
expressed in E. coli and purified using the histidine tag. ScFvs are not usually soluble in E. coli 
but have previously been shown to have a higher expression and more efficient purification from 
E. coli than S. cerevisiae (94).  
 
4.3.2.1 ScFv expression time course in E. coli 
Some of the scFvs isolated from the yeast two-hybrid screens were cloned into E. coli 
expression vector pET28b. pET28b is a E. coli protein expression vector. It contains a 
kanamycin resistant gene for plasmid selection and a histidine tag for protein purification. The 
cells were grown up in LB-kanamycin media, induced with IPTG at room temperature and time 
points were taken. The cells were ruptured under native and denaturing conditions, separated by 
SDS-PAGE, and stained with coomassie blue stain (Figure 4-8). 
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Figure 4-8: ScFv expression in E. coli.  
The scFv was induced for 24 hours and time points were taken. The cells were ruptured under 
native and denaturing conditions. Fifteen μL of each sample was separated in a 4% stacking 15% 
resolving SDS-PAGE and stained with Coomassie blue dye. Lane M, a pre-stained protein 
marker; lane 1, denatured scFv at three hours of induction; lane 2, natively expressed scFv and 
three hours of induction; lane 3, denatured scFv at four hours of induction; lane 4, natively 
expressed scFv at four hours of induction; lane 5, denatured scFv at five hours of induction; lane 
6, natively expressed scFv at five hours of induction; lane 7, denatured scFv at 21 hours of 
induction; lane 8, natively expressed scFv at 21 hours of induction. The lower arrow indicates 
where the cyclic scFv is approximated to run (36 kDa). The upper arrow indicates where the 
unprocessed cyclic scFv is approximated to run (48 kDa). The box highlights the N-intein 
domain. 
 
 
 
When expressed in E. coli, the cyclic scFv is approximately 36 kDa. (Figure 4-9) The 
best induction time for the cyclic scFv was 21 hours. More protein was isolated under denaturing 
conditions. The cyclic scFv was not present until 21 hours. This is similar to other reports that 
have induced the scFv for 16 hours at 24 °C (96). The unprocessed scFv will be present 
depending on the efficiency of the cyclization reaction. The unprocessed scFv is visible at 
approximately 48 kDa. There was a band that corresponds to the size of the N-intein domain (12 
kDa) (Figure 4-8). Since the N-intein domain is present it indicates that the intein is processing.  
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Figure 4-9: ScFv constructs expressed in E. coli.  
The unprocessed version of the scFv-intein will be visible where the intein mediated scFv 
cyclization reaction has not occurred. The unprocessed version in composed of the 6x Histidine 
tag (His) which is used to purify and identify the scFv, the C-intein (IC) and N-intein (IN) used in 
the intein-mediated cyclization process, The unprocessed scFv is approximately 48 kDa. The 
cyclic version of the scFv differs from unprocessed in that it has undergone the cyclization 
reaction cleaving off the IN domain (which should be visible in a SDS-PAGE) ultimately 
cyclizing the scFv making the cyclic scFv approximately 36 kDa. The linear version of the scFv 
does not contain any of the of the intein machinery and is approximately 31 kDa. 
 
 
 
4.3.2.2 ScFv histidine tag-nickel column purification 
A cyclic scFv was expressed as a fusion to 6x histidine tag using the pET28b expression 
plasmid. Cells expressing the cyclic scFv were induced and collected. The cells were ruptured by 
sonication. The cell lysate was denatured with 8 M urea and applied to the nickel beads. After an 
hour of incubation with the lysate, the beads were washed and eluted. Each sample was collected 
and separated in a SDS-PAGE (Figure 4-10).  
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Figure 4-10: ScFv purification from E. coli.  
Cells expressing a cyclic scFv were grown in LB-Kanamycin liquid media and induced with 
IPTG. A small sample of cells was taken before and after the induction and shown in the 
uninduced and induced lanes. The cell lysate was incubated with nickel beads. Lane M, standard 
pre-stained protein marker; lane 1, uninduced cells; lane 2, induced cells; lane 3, crude cell lysate 
before incubation with nickel beads; lane 4, flow through lysate that did not bind the nickel 
beads; lane 5, wash 1; lane 6, wash 2; lane 7, elution 1 from the nickel beads; lane 8, elution 8 
from the nickel beads. Only the proteins containing a histidine tag will be visible in the elutions. 
The lower arrow indicates where the cyclic scFv is approximated to run (36 kDa). The upper 
arrow indicates where the unprocessed cyclic scFv is approximated to run (48 kDa). The boxes 
highlight the N-intein (12 kDa). 
 
 
When the scFv was expressed in E. coli there are two main protein products purified from 
the nickel beads. There is a band that corresponds to the size of the cyclic scFv (36 kDa) and one 
that corresponds to the unprocessed scFv (48 kDa). The nickel beads were overloaded as 
indicated by the excess of protein in the flow through lane. There were bands in the crude and 
flow through samples that correspond to the size of the N-intein (12 kDa). The N-intein does not 
contain a histidine tag so it does not bind to the nickel beads as indicated by its presence only in 
the crude and flow through. The presence of the N-intein indicates that the intein is processing. 
Size exclusion was used to try and separate the three main bands from the histidine bead 
purification for further analysis of the cyclic scFv. The size exclusion was not successful in 
separating the bands. Further studies will have to be done to purify the cyclic scFv without the 
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contaminating bands in order to specifically analyze the cyclization. The three bands were 
analyzed on a mass spectrometer. The scFv was not visible on the mass spectrometer. The scFv 
may have been too large or not properly charged. Other groups who analyzed scFvs on the mass 
spectrometer have first digested the scFv prior to analysis (96). The proper conditions will have 
to be determined for analysis of the scFv on the mass spectrometer to determine if it is cyclic. 
 
4.3.2.3 Renaturation of scFv 
It has previously been shown that scFvs are difficult to purify in the native form from the 
cytoplasm of E. coli cells (97). To purify scFvs from the bacterial cytoplasm, most scFvs must 
first be denatured with urea or guanidium hydrochloride. When denaturing an scFv the ability to 
bind to protein L is eliminated. ScFvs will only bind to protein L when properly folded. To 
overcome this problem a basic renaturing protocol by Kou et al. was used to renature the scFvs 
(98). The scFv was denatured using 8 M urea and bound to the nickel beads (98). The scFv was 
renatured while still bound to the beads by washing it slowly with decreasing concentrations of 
urea. Most proteins cannot refold properly in a short amount of time (99). It must be slowly 
exposed to an environment in which it can start to refold (99). 
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Figure 4-11: ScFv expression and renaturation.  
A cyclic scFv was expressed in E. coli, grown in LB-Kanamycin liquid media and induced with 
IPTG. The cell lysate was incubated with nickel beads and washed with decreasing 
concentrations of urea in a 2 M gradient. Lane M, standard pre-stained protein marker; lane 1, 
crude cell lysate before incubation with nickel beads; lane 2, flow through lysate that did not 
bind the nickel beads; lane 3, wash 1; lane 4, wash 2; and lane 5, elution 1 from the nickel beads. 
Only the proteins containing a histidine tag will be visible in the elutions. The lower arrow 
indicates the cyclic scFv (36 kDa). The upper arrow indicates where the unprocessed cyclic scFv 
is (48 kDa). The boxes highlight the N-intein (12 kDa). 
 
 
 
After washing the nickel beads with the scFv still bound, it was eluted. The samples from 
each step were separated in SDS-PAGE (Figure 4-11). There were three main bands eluted off 
the nickel beads after refolding. One corresponds to the cyclic scFv (36 kDa) and two correspond 
to the size of the unprocessed scFv (48 kDa). In the crude and flow through samples there is a 
band that corresponds to the size of the N-intein (12 kDa). It is impossible to tell from the SDS-
PAGE what percent of the scFvs are renatured.  
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Previous studies have reported that <20% of the scFv will be refolded using this method. 
Further refolding occurred upon the addition of an oxidizing agent (100). ScFvs have been 
previously renatured; their activity has been restored upon refolding (98).   
 
4.3.2.4 Protein L purification of scFv 
Elution one from the renatured scFv was applied to the protein L beads and incubated 
overnight. The beads were washed, eluted and separated by SDS-PAGE (Figure 4-12).  
 
 
 
Figure 4-12: ScFv Protein L purification.  
Elution one of renatured scFv from the nickel beads was incubated with protein L beads. After 
eluting the scFv off the protein L beads were heated up to 95 ˚C in loading dye to extract what 
was left on the beads. A control with only protein L beads was also heated in the same way. Lane 
M, standard pre-stained protein marker; lane 1, crude cell lysate before incubation with protein L 
beads; lane 2, flow through lysate that did not bind the protein L beads; lane 3 wash 1; lane 4, 
elution 1; lane 5 elution 2; lane 6, elution 3; lane 7, protein L beads heated after elution; lane 8, 
protein L beads heated alone. Only the proteins containing kappa light chains will bind to the 
protein L beads. The lower arrow indicates where the cyclic scFv is approximated to run (36 
kDa). The upper arrow indicates where the unprocessed cyclic scFv is approximated to run (48 
kDa). The boxes highlight the N-intein domain (12 kDa). 
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There was a low concentration of the scFv that binds to the protein L beads. There were 
two main bands that bind to the protein L column, which are visible in the loaded sample, the 
eluted sample and the protein L heated sample. There were other visible bands from the beads, if 
the bands are not visible in lane 1 they are artifacts from the protein L beads. The two main 
bands correspond to the cyclic scFv (36 kDa) and the unprocessed scFv (48 kDa). There was not 
very much protein eluting off the protein L beads. This could be due to a very small percentage 
of scFv actually refolding as has previously been shown (98). Refolding scFvs using only a 
decreasing urea gradient produces small yields of refolded scFv (>20%) (98). Using a decreasing 
gradient in correlation with an increasing pH gradient the refolded yield can be increased to 25% 
(101). By using a decreasing urea gradient in correlation with an oxidizing agent the yield of 
refolded scFv can be increased to as much as 75% if added at the right urea concentration (98). 
 
 
 
 81 
 
Chapter 5 Discussion 
 
By constructing large, diverse scFv libraries the effects of different parameters used to 
vary the CDR compositions and the scFv were studied to determine their impacts on binding 
capacity. In particular, cyclizing the scFv conformation allowed for more interactions with a set 
number of protein domains. This trend was reinforced by the statistically significant difference 
(P value < 0.05) between the cyclic and linear binding capacities.  
The libraries with three variable CDRs had a higher binding capacity than the libraries 
with four CDRs in eleven out of thirteen screens. The increased diversity imposed by the fourth 
diversified CDR did not produce a larger binding capacity despite the increased diversity. The 
fourth diversified CDR may have created a negative effect on scFv folding and thus decreased 
the library binding capacity. In most of the screens the three CDR libraries had a statistically 
larger binding capacity than the four CDR libraries. 
In a study by Fellouse et al., two Fab phage display libraries were made, one with all 
three CDRs on the heavy chain varied and the other with the heavy chain CDRs and CDR L3 
varied (9). The CDRs were diversified with tyrosine and serine. They found that most of the 
clones isolated from the library had the additional CDR L3 (9). The isolated clones from the 
same libraries had similar sequences but are different between the two libraries (9). This result 
concludes that the variable CDR L3 influences the specificity (9). In a similar study, four 
libraries were made; two were the same as described above and the other two were more diverse 
(81). The second least diverse library, the library with a variable heavy chain and variable L3 
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isolated the highest number of binders (81). These studies indicate that diversity may not dictate 
binding capacity. 
The binding capacity results for the three CDR scFv libraries showed that the four amino 
acid libraries had a higher binding capacity then the two amino acid libraries. Three out of six 
screens had statistically significant differences (P value < 0.05). The binding capacity results for 
the four CDR libraries comparing two and four amino acid libraries were inconclusive. All sets 
of data showed a mix of results, which is signified by the random statistical significance of the 
results.  
In a previous study, four different Fab libraries were created with the CDRs varied with 
tyrosine and serine (81). The simplest libraries had the heavy chain varied and the other had the 
heavy chain and light chain CDR L3 varied (81). The two more complex libraries contained 
additional variable amino acids throughout the CDRs (81). This is interesting because it does not 
reflect the most diverse library as obtaining the most interactions (81). These results indicate that 
a more diverse library in terms of CDR variability does not necessarily dictate more protein 
interactions. 
Isolated scFvs were successfully expressed in S. cerevisiae and E. coli. The scFvs were 
not successfully isolated from S. cerevisiae with protein L. ScFvs have not previously been 
purified using protein L from S. cerevisiae. Many research groups purify scFvs from S. 
cerevisiae using metal chromatography and a histidine tag (102). Most groups use Pichia 
pastoris for scFv expression and purification instead of S. cerevisiae. They usually use a 
histidine tag to isolate the scFvs from the cell lysate (103,104) or after they are secreted into the 
media (105). A few groups have used protein L to isolate antibody fusions secreted into the 
media expressed in Pichia pastoris (106). It is unknown why the scFvs were not successfully 
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isolated using protein L. It is also interesting, since scFvs isolated with protein L from S. 
cerevisiae cells has not been previously reported. Previously Villani et al. reported purifying 
active scFvs from bacterial cytoplasm able to bind their target but unable to bind protein L for 
efficient purification (65).  
ScFvs were successfully denatured and purified from the E. coli cytoplasm using nickel 
beads. ScFvs usually form insoluble inclusion bodies within E. coli cells and have to be 
denatured to purify them. To be functional scFvs must be properly refolded. There are very few 
reports on soluble scFvs isolated from the E. coli cytoplasm. They usually involve tethering of a 
soluble fusion protein (107); or more recently, using a soluble, stably expressed scFv framework 
(65). This scFv framework is able to bind its target in vitro after purification from the bacterial 
cytoplasm, however, is unable to bind to protein L (65). This indicates that protein L may not 
indicate proper folding of the scFvs since active scFvs were unable to bind to it. In most studies 
researchers use histidine tags to isolate scFvs from bacterial cell lysate or from the media the 
cells are growing in. When the scFvs are isolated from the cytoplasm they usually have to be 
denatured and then renatured to analyze activity or folding patterns. In many studies scFvs are 
secreted into the periplasm, which is an oxidizing environment that allows scFvs to fold 
properly. In the periplasm, expression level is often low and the formation of inclusion bodies is 
frequent despite its oxidizing character (108). The cytoplasm is a desirable expression 
compartment because although the scFvs are often unfolded, the concentration of proteins 
isolated is much higher (97).  
The scFvs bound to the histidine beads were renatured and incubated with protein L 
beads. It was observed that very little protein bound to the protein L beads. Previous studies 
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report that <20 % of the scFv refold using this method (98). This may be the reason for such a 
small amount of protein eluted off the protein L column.  
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Chapter 6 Conclusion 
 
In conclusion, cyclizing scFv libraries increases binding capacity. ScFv libraries with 
four amino acids produce a larger binding capacity than two amino acids in the three CDR 
libraries. Diversifying the fourth CDR, CDR L3 on the scFv decreases the binding capacity 
despite the increased diversity. The four CDR libraries had no trend when comparing the two and 
four amino acids. The goal of this project was to determine minimal parameters that could be 
varied in creating scFv libraries without sacrificing the ability to purify highly specific 
interactions. Minimal diversity limited to tyrosine and serine can be used with as little as 18 
variable residues within the CDRs. With respect to library design if a new library were to be 
created, cyclization of the scFvs is recommended, which has been shown in this study to increase 
the binding ability. The new library would also be produced with three diversified CDRs and 
four amino acids. It would be interesting to determine the behavior of the specific scFvs within a 
human cell, where the target would be endogenous. 
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Chapter 7 Recommendations 
 
Future recommendations for this project include optimizing the purification of scFvs to 
study the effect of cyclization. Purification in yeast can be performed using an HA-tag by 
denaturing the scFv before purification from yeast. Purification from E. coli involves optimizing 
the renaturing step, which can be achieved by adding an oxidizing reagent (98). Also, the three 
bands purified from cyclic scFvs expressed in E. coli will have to be separated to enable the 
study of the cyclic scFv alone. This can be achieved by cloning with two histidine tags, by using 
a more accurately size exclusion column, or by gel extraction. 
This study has shown that the scFv is processing, which is a good indication that it is also 
cyclizing. This can be confirmed by studying the cyclic scFv with mass spectrometry. If the scFv 
is cyclic, the affect cyclization has on the scFv in terms of binding ability; affinity, stability and 
solubility must be determined. If the effect is as significant as shown in this study, problematic 
factors plaguing scFvs such as stability may be resolved. Binding assays can be done using 
surface plasmon resonance for example, to determine if the cyclic version is able to bind more 
effectively. Chemical and temperature unfolding and refolding studies can be performed to 
compare the stability of cyclic scFv and linear scFv. Solubility assays can be done to determine 
if cyclizing scFvs increases their solubility and reduces the formation of scFv multimers.
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Appendix 
Raw Screen Data 
 
 
Table A-1 Raw Screen Data. 
This is the raw data from each screen, the numbers counted from each plate. They have not been 
normalized to functionality or actual diploids plated, which was counted twice in triplicate. The 
first column shows the library name linear =L or cyclic = c, K = four amino acids or T = two 
amino acids. The numbers from screens 1, 2, 3, 4, 5 are shown in the few columns. The average 
of the screens is shown in the seventh column. The standard deviation (SD) is shown in the 
eighth column. The number of diploids screened is shown in the next column. The functional 
diversity as defined by correct sequence is shown in the second last column. The interactions per 
functional diversity (FD) multiplied by ten million is shown in the last column. 
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Screen 
1
1 2 3 4 5 Average SD Diploids
Functional 
Diversity
Interactions/
FD*1x10^7
LK3 882 902 904 847 842 875 30 2.60E+05 0.73 4612.2
cK3 NA NA NA NA NA NA NA NA 0.60 NA
LK4 404 124 105 131 101 173 130 2.60E+05 0.52 1279.6
cK4 304 403 402 403 262 355 67 2.60E+05 0.41 3328.3
LT3 108 58 84 98 75 85 20 2.60E+05 0.67 485.6
cT3 NA NA NA NA NA NA NA NA 0.60 NA
LT4 6 21 32 7 11 15 11 2.60E+05 0.51 116.1
cT4 264 185 102 410 358 264 125 2.60E+05 0.65 1560.9
Screen 
2
1 2 3 4 5 Average SD Diploids
Functional 
Diversity
Interactions/
FD*1x10^7
LK3 296 112 0 0 ND 102 140 1.00E+06 0.73 139.7
cK3 NA NA NA NA NA NA NA NA 0.60 NA
LK4 168 ND 92 50 42 88 58 1.00E+06 0.52 169.2
cK4 148 156 50 148 74 115 49 1.00E+06 0.41 281.0
LT3 26 52 46 35 19 36 14 1.00E+06 0.67 53.1
cT3 NA NA NA NA NA NA NA NA 0.60 NA
LT4 92 59 47 30 65 59 23 1.00E+06 0.51 114.9
cT4 184 144 168 128 ND 156 25 1.00E+06 0.65 240.0
Screen 
3
1 2 3 4 5 Average SD Diploids
Functional 
Diversity
Interactions/
FD*1x10^7
LK3 84 97 125 193 138 127 43 6.00E+06 0.73 29.1
cK3 NA NA NA NA NA NA NA NA 0.60 NA
LK4 49 54 67 51 64 57 8 6.00E+06 0.52 18.3
cK4 53 55 68 69 80 65 11 6.00E+06 0.41 26.4
LT3 119 124 160 170 147 144 22 6.00E+06 0.67 35.8
cT3 NA NA NA NA NA NA NA NA 0.60 NA
LT4 80 88 118 94 87 93 15 6.00E+06 0.51 30.5
cT4 147 158 163 154 201 165 21 6.00E+06 0.65 42.2
Screen 
4
1 2 3 4 5 Average SD Diploids
Functional 
Diversity
Interactions/
FD*1x10^7
LK3 104 100 129 95 107 107 13 2.02E+06 0.73 72.6
cK3 NA NA NA NA NA NA NA NA 0.60 NA
LK4 23 15 24 26 22 22 4 2.37E+06 0.52 17.9
cK4 83 112 106 89 ND 98 14 1.90E+06 0.41 125.2
LT3 41 40 75 21 37 43 20 1.93E+06 0.67 33.1
cT3 73 42 42 88 61 61 20 1.75E+06 0.60 58.3
LT4 31 20 17 14 ND 21 7 1.33E+06 0.51 30.2
cT4 54 82 36 54 57 57 16 2.13E+06 0.65 40.9
Screen 
5
1 2 3 4 5 Average SD Diploids
Functional 
Diversity
Interactions/
FD*1x10^7
LK3 84 163 130 123 107 121 29 3.32E+07 0.73 50.1
cK3 263 211 231 190 216 222 27 2.92E+07 0.60 126.8
LK4 19 17 13 9 27 17 7 4.59E+07 0.52 7.1
cK4 47 52 30 31 33 39 10 4.63E+07 0.41 20.3
LT3 20 23 17 19 27 21 4 3.31E+07 0.67 9.6
cT3 31 39 36 33 45 37 5 3.77E+07 0.60 16.3
LT4 13 7 19 8 9 11 5 3.67E+07 0.51 6.0
cT4 44 43 52 47 54 48 5 3.14E+07 0.65 23.5
